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ABSTRACT 
 
Pancreatic ductal adenocarcinoma (PDAC) ranks among the poorest prognoses for 
cancer patients, with an estimated 5-year survival of just 8%. The stagnant survival rates 
are a result of late detection, chemoresistance, and an aggressive tumor phenotype. Too 
few patients are eligible for surgery, which results in an urgent need for more effective 
chemotherapeutic treatment options.  
 
One promising pharmacological advancement is currently undergoing a Phase II clinical 
trial and has been studied by our laboratory. Triptolide is a Chinese herb, which has 
shown to be very effective in eliminating pancreatic cancer cells in vitro and in vivo. In 
conjunction with the Medicinal Chemistry Department at the University of Minnesota, a 
prodrug of triptolide, named Minnelide™, has been synthesized. Our laboratory has 
since studied triptolide and Minnelide™ extensively, in order to determine the 
mechanisms of action.   
 
The initial study in this dissertation precipitated based on an earlier finding in the Saluja 
laboratory that triptolide not only downregulates heat shock protein 70 (HSP70) and 
specificity protein 1 (SP1), but also causes chronic endoplasmic reticulum (ER) stress 
and cell death. Our study shows that downregulating SP1, a transcription factor that is 
overexpressed in pancreatic cancer, activates the unfolded protein response (UPR) and 
results in chronic ER stress. We further show that inhibition of SP1, as well as inducing 
ER stress, leads to lysosomal membrane permeabilization (LMP), a sustained 
accumulation of cytosolic calcium, and eventually cell death in pancreatic cancer.  
 
Even though ER stress can result in cell death, it is initially a homeostatic mechanism, 
which aims to protect cells. This led us to ask what role acute ER stress and UPR plays 
in pancreatic cancer. We show that modulating glucose regulatory protein 78 (GRP78), 
the master regulator of the UPR, can have a profound effect on multiple pathways that 
mediate chemoresistance. Our study showed for the first time that knockdown of GRP78 
can diminish efflux activity of ATP-binding cassette (ABC) transporters, and it can 
decrease the antioxidant response resulting in an accumulation of reactive oxygen 
species (ROS). We also show that these effects can be mediated by the activity of SP1.  
	v		
 
Our investigation into acute ER stress led to further studies to characterize the UPR 
signaling in pancreatic cancer. We show that shGRP78 dysregulates multiple 
transcriptomic and proteomic pathways important in cancer (proliferation, survival, fatty 
acid metabolism). GRP78 downregulation decreases stemness and self-renewal 
properties in vitro. In vivo studies demonstrate that GRP78 knockdown results in delayed 
tumor initiation, and decreased tumor growth. Further, downregulation of GRP78 results 
in fatty acid metabolism dysregulation.  
 
The last study in this dissertation focuses on the tumor microenvironment and SP1 
oncogenic signaling. We evaluated the transcriptomic profiling conducted after treatment 
with triptolide revealed deregulation of the transforming growth factor beta (TGF-β) 
signaling pathway in cancer-associate fibroblasts (CAFs), resulting in an apparent 
reversal of their activated state to a quiescent, non-proliferative state. The neighboring 
epithelial cells exhibited a decrease in oncogenic signaling as manifested by 
downregulation of SP1. Our findings suggest that approaches to inactivate CAFs and 
prevent tumor-stromal crosstalk may offer a viable strategy to treat pancreatic cancer. 
 
These studies underscore the importance of ER stress and understanding the complex 
balance of adaptation versus cell death in pancreatic cancer. We have identified SP1 
and GRP78 as potential targets for future PDAC therapies. These findings have clinical 
relevance as both SP1 and GRP78 are overexpressed in pancreatic cancer patients and 
increased expression of these proteins are indicative of poor prognosis.  
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INTRODUCTION 	
Challenges in treating pancreatic ductal adenocarcinoma 
Pancreatic ductal adenocarcinoma (PDAC) ranks among the poorest prognoses for 
cancer patients, with an overall estimated 5-year survival of just 8%. The estimated 5-
year survival rate for local disease is 32%, whereas regional metastasis is 12%, and 
distant metastasis is 3%1. In 2018, it is estimated that 55,440 people will be diagnosed 
with pancreatic cancer, and 44,330 people will succumb to the disease1. These survival 
statistics have remained relatively unchanged for over 50 years.  
 
Symptoms of pancreatic cancer are general (weight loss, abdominal discomfort, 
nausea), and there are no reliable biomarkers, which often makes an early diagnosis 
difficult. Fewer than 20% of patients diagnosed with pancreatic cancer are eligible for 
surgery. Unfortunately, the majority of new cases are diagnosed with distant metastasis 
(52%), making them ineligible for surgical resection (SEER)1. Chemoresistance presents 
an ongoing challenge to researchers and clinicians, and is responsible for greater than 
90% of therapeutic failures2, 3. There are multiple proposed mechanisms of resistance, 
including reduced drug uptake or increased drug efflux, alteration of the drug target, and 
reduced sensitivity to cell death2-4. Thus, the stagnant survival rates are a result of late 
detection, an aggressive tumor phenotype, and chemoresistance. 
 
The approved chemotherapeutics are nucleoside analogs, DNA-crosslinking agents, and 
microtubule inhibitors; all targeting rapidly proliferating cells. Gemcitabine (a nucleoside 
analog) monotherapy was approved as a first-line treatment for patients with locally 
advanced or metastatic pancreatic cancer in 1996, showing a median survival of 5.65 
months5. The current standard of care consists of gemcitabine in combination with 
Abraxane/nab-paclitaxel (albumin-bound microtubule poison, paclitaxel). Abraxane and 
gemcitabine combination extends survival to 8.5 months6. The chemotherapeutic 
cocktail, named FOLFIRINOX, consists of 5-Fluorouracil (5-FU), leucovorin, irinotecan, 
and oxaliplatin. FOLFIRINOX extends the median survival to 11 months, but is 
recommended for only a small subset of patients in good performance status7. There 
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have been other drugs combined with gemcitabine, but the survival benefit was 
comparable to gemcitabine alone. Overall, the chemotherapeutic agents that are 
currently approved for pancreatic cancer are largely ineffective. 
 
There are a variety of chemotherapeutics in development and clinical trials, as well as a 
variety of therapeutic combinations and techniques. Recently, ficlatuzumab, a 
hepatocyte growth factor (HGF) inhibitory monoclonal antibody completed a Phase I 
clinical trial for advanced solid tumors and liver metastases (Clinicaltrials.gov; 
NCT00969410). However, none of the enrolled patients had a reduction in tumor size, 
but rather, achieved “stable” disease8. Ficlatuzumab will now be tested in combination 
with gemcitabine and nab-paclitaxel in a Phase I study for pancreatic cancer 
(Clinicaltrials.gov; NCT03316599). Preclinical studies using programmed death receptor 
1 (PD1) blockade show an increase in survival in the KPC murine model. α-PD1 in 
combination with gemcitabine and nab-paclitaxel is undergoing a Phase II clinical trial in 
pancreatic cancer (Clinicaltrials.gov; NCT03214250).  
 
One promising pharmacological advancement, Minnelide™, is currently undergoing a 
Phase II clinical trial for GI cancers. Minnelide™ is a prodrug of a compound called 
triptolide, derived from the Chinese herb Tripterygium wilfordii. Preclinical studies 
conducted by our laboratory have shown significant reduction in tumor size, metastasis, 
and tumor-initiating cells9-21. The following studies detailed in this dissertation 
precipitated based on an earlier finding in the Saluja laboratory that triptolide not only 
downregulates heat shock protein 70 (HSP70) and specificity protein 1 (SP1), but also 
causes chronic endoplasmic reticulum (ER) stress leading to pancreatic cancer cell 
death15, 20, 22, 23.  
 
SP1 in Pancreatic Ductal Adenocarcinoma  
SP1 is a zinc-finger transcription factor, with a GC-rich binding sequence24-27. It regulates 
multiple biological functions, including cell growth, differentiation, angiogenesis, and 
survival; its dysregulation, therefore, can aid in several hallmarks of cancer, leading to 
tumor progression and metastasis15, 24, 28. SP1 is essential for embryological 
development of the pancreas, and SP1-/- murine models die 10 days post-gestation26, 29. 
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As cells become terminally differentiated, SP1 is SUMOylated and ubiquitinated, which 
inactivates the transcription factor in adult pancreata26. SP1 becomes overexpressed in 
PDAC, but the mechanism as to how is unclear. Further, studies from our laboratory 
have shown that SP1 is not expressed in acute or chronic pancreatitis, or endothelial 
cells, suggesting that SP1 overexpression is unique to cancer cells, and may offer a 
protective role in cancer. It has been shown from patient tumors, that higher levels of 
SP1 expression correlate with poor prognosis (Figure 1) and metastasis26.  
 
 
Figure 1:  SP1 overexpression correlates with poor survival in patients 
with pancreatic cancer 
5-year survival for high expression is 13%, whereas low expression is 
56%. Data is from Human Protein Atlas. 
 
ER stress and the Unfolded Protein Response 
ER stress is a well-characterized homeostatic mechanism, but arguably 
underappreciated considering its role in cells. The ER is fundamental in maintaining 
secretory protein biosynthesis, a site for sterol and phospholipid synthesis, as well as a 
major calcium storage site4, 7, 30-33.  
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Newly synthesized secretory and surface proteins enter the ER where chaperone 
proteins aid in folding into their tertiary structures4, 31, 32. Only properly folded proteins are 
exported from the ER to their respective destinations, and misfolded proteins get 
retained and/or degraded30-33. When misfolded or unfolded proteins accumulate inside 
the ER, it initiates the unfolded protein response (UPR). The UPR is the homeostatic 
mechanism that is often referred to as ER stress. UPR activation is initially an adaptive 
response to stressful stimuli7, 30-33. UPR intracellular signaling is activated through three 
transmembrane sensors:  inositol-requiring enzyme 1 (IRE1-α), protein kinase RNA-like 
ER kinase (PERK), and activating transcription factor 6 (ATF6)7, 30-33. Without stress, 
these sensors are kept inactive by binding to glucose regulatory protein 78 (GRP78), an 
ER-resident folding chaperone protein. Upon stress, misfolded or unfolded proteins 
sequester GRP78 from the sensors, allowing for UPR signaling to commence4, 7, 32, 33.  
 
IRE1 activation is immediate and leads to X box protein 1 (XBP1) mRNA cleavage, 
resulting in a 26 base pair excision and a transcription factor, XBP1s. IRE1-XBP1s 
increases protein folding and trafficking7, 32, 33. Downstream of PERK activation, 
eukaryotic initiation factor 2α (eIF2α) is phosphorylated and global translation is 
attenuated7, 30, 32, 33. This global stop allows for only UPR genes to be transcribed and 
translated, allowing for more folding chaperones to be made to alleviate the unfolded 
protein burden7, 32, 33. Nuclear factor erythroid 2-related factor 2 (NRF2) is also activated 
upon PERK activation, which is necessary for the antioxidant response. Finally, ATF6α 
gets trafficked to the Golgi apparatus, where two proteases (S1P and S2P) cleave 
ATF6α into an active transcription factor, ATF6α-fragment7, 32, 33. Multiple studies have 
sought to understand the individual signaling cascades of the UPR, by using knockout 
mouse models. Knockout models of IRE1α and its downstream transcription factor, 
XBP1s, as well as GRP78 have shown to be embryonic lethal, suggesting that a 
functional UPR is essential for growth and cell survival7, 31, 34-41.  
 
In addition to activating the UPR under stress, the ER actually dilates in size, in order to 
accommodate more unfolded proteins. As a result, part of the UPR transcribed genes 
are involved in membrane lipid biogenesis31. 
 
Not surprisingly, ER stress and the UPR are involved in many diseases, including 
	5	
cancer. Cancers generally promote a hostile tumor microenvironment, which can result 
in hypoxia and nutrient deprivation, and ultimately activate the UPR. Because the UPR is 
an adaptive mechanism, cancer utilizes it to its advantage for cancer cell survival. UPR-
related proteins have been described in multiple cancers. For example, in breast cancer, 
GRP78 is more highly expressed in estrogen receptor negative cancers than positive32. 
In colon cancer, GRP78 expression is correlated with malignant cells and a higher tumor 
stage32. GRP78 is also correlated with shorter survival and castration-resistant subtypes 
of prostate cancer32. 
 
Chemoresistance can occur through activating parts of the UPR. For example, elevated 
levels of glutathione, which is involved in drug metabolism and downstream of NRF2 
activation, has been associated with platinum-resistance3. Additionally, thiol glutathione 
(GSH) can conjugate drugs, making them ideal substrates for ABC-transporters2. 
Hypoxia-induced UPR has been shown to reduce the number of rapidly proliferating 
cells, causing G0 arrest, as well has inducing pro-survival signaling3. 
 
The UPR has been described to play a role in metastasis, cell dormancy, angiogenesis, 
immune tolerance, metabolic status, and chemoresistance2, 3, 33. However, as many 
advantages the UPR can provide to cancer cell growth and survival, cancer cells are still 
susceptible to chronic or prolonged UPR signaling, which can activate cell death 
pathways7, 32. 
 
PDAC tumor microenvironment 
There are multiple cellular and acellular components, which make up the tumor 
microenvironment in pancreatic cancer. There are the epithelial cells, which diverge into 
non-tumor initiating cells and tumor initiating cells; there is a dense stroma, consisting of 
pancreatic stellate cells (PSCs), cancer- associated fibroblasts (CAFs), and extracellular 
matrix (ECM) that develop with the tumor; there are also the infiltrating immune cells 
(tumor associated macrophages and neutrophils)42. Due to the bulk of rapidly 
proliferating cells and the surrounding dense stroma, the centers of pancreatic tumors 
tend to be hypoxic in nature42, 43. Hypoxia is one of the extrinsic driving forces of 
activating the UPR and chemoresistance. Further, hypoxia-inducible factor 1 (HIF1) 
	6	
expression has been reported to act as a cofactor with XBP1s for transcription.  
 
The role of the stroma is a controversial component in the pancreatic tumor 
microenvironment. As the stroma develops, the interstitial pressure constricts blood 
vessels, thereby not only reducing flow of oxygen and nutrients but also 
chemotherapeutic compounds44, 45. However, only targeting the stroma has not yielded 
significant benefit it terms of the survival in pancreatic cancer patients46, 47. A study by 
Rhim et al. has demonstrated that the role of stroma in pancreatic cancer may be 
restraining, and thus, inhibiting it would likely be detrimental for survival and this would 
result in extensive metastasis of the cancer48. However, a study by Banerjee et al. has 
found that Minnelide™ targets the stroma and the epithelial tumor cells. As a result, they 
found reduced stromal components hyaluronan and collagen, improved vasculature 
function, and increased intra-tumoral drug delivery12. 
 
In clinical practice, combination therapy is generally preferred over monotherapy, in 
order to manage dose-limiting toxicities and to reduce the onset of drug resistance. The 
ideal treatment option will incorporate a therapy that targets rapidly proliferating cells, 
quiescent tumor-initiating cells, as well as the dense desmoplastic stroma that surrounds 
the tumor.  
 
In this dissertation, I will present four studies that centralize around ER stress, UPR 
signaling, and SP1-mediated oncogenic signaling. Chapter 1 discusses how SP1 
downregulation can result in chronic ER stress and cell death. Chapter 2 covers how 
acute ER stress and UPR signaling can result in chemoresistance, and targeting the 
master regulator GRP78, or GRP78 through SP1 downregulation can re-sensitize 
resistant cells to chemotherapeutics. In Chapter 3, we further investigate the implications 
of GRP78 in the aggressive phenotype of pancreatic cancer, through the use of a stable 
shGRP78 cell line. Lastly, in Chapter 4, we explore the mechanism of action of 
triptolide/Minnelide™ on the crosstalk between tumor epithelial cells and stromal cells, 
and how triptolide can be used to inactivate stromal cells, thereby decreasing the 
oncogenic signaling of SP1.  
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CHAPTER 1:  CHRONIC ER STRESS IN CANCER BIOLOGY 
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SUMMARY 
 
Background:  Endoplasmic reticulum (ER) stress initiates an important mechanism for 
cell adaptation and survival, named the unfolded protein response (UPR). Severe or 
chronic/prolonged UPR can breach the threshold for survival and lead to cell death. 
There is a fundamental gap in knowledge on the molecular mechanism of how chronic 
ER stress is stimulated and leads to cell death in pancreatic ductal adenocarcinoma 
(PDAC).  
 
Methods:  MIA PaCa-2, S2-VP10, and S2-013 cells were treated with pharmacological 
inhibitors or genetically silenced using ON-TARGETplus SMARTpool siRNA. ChIP and 
an ERSE reporter assay were used to determine the loss of ER stress response by 
downregulation of glucose regulatory protein 78 (GRP78). Lysosomal activity was 
measured with a cathepsin B activity assay. Intracellular calcium was measured by 
staining with calcium orange dye and measured with a spectrophotometer. MIA PaCa-2 
cells were injected into athymic nude mice subcutaneously and treated with two doses of 
mithramycin [specificity protein 1 (SP1) inhibitor] for four weeks. 
 
Results:  Our study shows that downregulating SP1, a transcription factor that is 
overexpressed in pancreatic cancer, activates UPR and results in chronic ER stress. In 
addition, downregulation of SP1 results in its decreased binding to the ER stress 
response element present in the promoter region of GRP78, the master regulator of ER 
stress, thereby preventing homeostasis. We further show that inhibition of SP1, as well 
as induction of ER stress, leads to lysosomal membrane permeabilization (LMP), a 
sustained accumulation of cytosolic calcium, and eventually cell death in pancreatic 
cancer.  
 
Conclusion:  This study underscores the importance of ER stress and understanding the 
complex balance of adaptation versus cell death in pancreatic cancer. The current study 
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identified SP1 and GRP78 as potential targets for future therapeutics in PDAC; 
discovered a protective role of SP1 in cancer; as well as further detailed ER stress 
response in cell death mechanisms. 
 
INTRODUCTION 
 
Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. It 
was estimated that in 2016, 53,070 people would be diagnosed with pancreatic cancer 
and nearly 42,000 would die from it in the United States alone49. There is currently no 
effective treatment approved for pancreatic cancer. Gemcitabine has been the standard 
of care for pancreatic cancer for 19 years; however, it adds a survival advantage of only 
6.8 months50. The most widely used treatment algorithms employing gemcitabine in 
combination with nanoparticle bound albumin (nab-paclitaxel) or the chemo-intensive 
regimen of FOLFIRINOX (5-fluoruracil, oxaliplatin, and folate supplementation), offer a 
meager survival benefit of a few weeks over traditional gemcitabine alone regimens6. 
Preclinical studies from our laboratory have shown that triptolide, a diterpene triepoxide 
from a Chinese herb, is cytotoxic in a number of cancers, including pancreatic ductal 
adenocarcinoma (PDAC)9. Our laboratory has synthesized Minnelide™, a water-soluble 
prodrug of triptolide, which just completed Phase I clinical trials9. Though the exact 
mechanism of triptolide induced cell death remains unknown, our previous studies have 
indicated that triptolide-induced cell death is caused by chronic Endoplasmic Reticulum 
(ER) stress23. However, there remains a gap in knowledge on the molecular mechanism 
of how ER stress is stimulated and how chronic ER stress causes cell death in 
pancreatic cancer.  
 
The ER is a site for calcium storage, protein folding, and modifications29, 51-54. ER stress 
is a well-characterized condition that plays a role in multiple pathologies, including 
neuro-degeneration, rheumatoid arthritis, atherosclerosis, and many types of cancer54, 55. 
A variety of cellular insults can result in ER stress, including hypoxia, calcium 
fluctuations, oxidative stress, and nutrient deprivation52-54. When ER function is impaired 
during stress, the cell initiates the evolutionarily conserved unfolded protein response 
(UPR), which helps to adapt and survive stressful conditions. Three transmembrane 
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sensors mediate the UPR:  inositol-requiring enzyme 1 (IRE1), activating transcription 
factor 6 (ATF6), and protein kinase-like ER kinase (PERK). During normal conditions, 
these three sensors are kept silent by associating with glucose regulatory protein 78 
(GRP78), a protein chaperone. Upon experiencing stress, GRP78 will disassociate from 
the sensors to activate the UPR. In cases of severe or chronic/prolonged ER stress, the 
UPR is overwhelmed, and the cell will initiate cell death pathways52. In some diseases 
like neuro-degeneration or type II diabetes, recent studies show promise in inhibiting ER 
stress, resulting in cell survival55. However, in cancer, treatment strategies aim to 
prevent ER homeostasis to cause cell death55. 
 
Multiple studies have underscored the importance of specificity protein 1 (SP1), a 
transcription factor, in malignant tissues. In fact, SP1 has recently been described as a 
non-oncogene addiction gene in cancer56. SP1 has been reported to regulate many 
biological functions, including cell growth, differentiation, survival, tumor progression, 
and metastasis15, 24, 26, 28, 56-58. It has also been reported in colon, gastric, pancreatic, and 
breast cancers that SP1 is overexpressed, whereas minimal to no SP1 expression is 
detected in normal differentiated cells15, 24, 26, 28, 56, 57. Owing to its binding sites present in 
a large number of genes, downregulation of SP1 is likely to have a profound effect on 
cancer cell survival. Further, in the context of ER stress, it has been reported by Safe et 
al, that SP1 binding is necessary for the UPR59. However, it has not been determined 
whether chronic ER stress as a result of SP1 downregulation leads to cell death in 
pancreatic cancer. 
 
One of the hallmarks of cancer cells is their resistance to apoptosis. Thus, a number of 
studies have been focused on overcoming this resistance by targeting pathways leading 
to apoptosis. Lysosomal membrane permeabilization (LMP) often precedes apoptosis in 
response to cytotoxic compounds in cancer cells60, 61. Lysosomes contain a number of 
hydrolytic enzymes, and are essential in autophagy-mediated recycling and cell 
survival60, 61. Due to the contents of lysosomes, they have been described as “suicide 
bags”, and when permeabilized, the contents can be released into the cytosol, leading to 
unregulated proteolysis and cell death60.  
 
Calcium regulation is also an important component of cell survival and thus, cell death29, 
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51, 62. Calcium is also a second messenger to a variety of cellular processes, including 
protein synthesis and folding, proliferation, and apoptosis51, 63. The ER and mitochondria 
provide the major storages sites of calcium for the cell, and a dysregulation of calcium 
can not only cause ER stress, but also can also be a consequence of ER stress, and 
lead to cell death29, 62, 64.  
 
Previous studies from our laboratory have shown that triptolide results in chronic ER 
stress by downregulating GRP78, leading to cell death in pancreatic cancer23. In addition 
to these effects, triptolide downregulates the activity of SP115, thereby starting a cascade 
of events that lead to downregulation of several pro-survival genes. In this study, we 
show that SP1 downregulation in pancreatic cancer results in chronic ER stress, which 
in turn leads to a sustained increase in cytosolic calcium, LMP, and cell death. 
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RESULTS 	
SP1 downregulation causes ER stress and tumor regression 
 
We have previously shown that SP1 downregulation with mithramycin (MTH) results in 
pancreatic cancer cell death15. In the current study, we showed that both 0.3 and 0.6 
mg/kg MTH decreased tumor burden in a subcutaneous model with MIA PaCa-2 cells in 
athymic nude mice (Figure 1.1A), which is consistent with our previous work. Table 1.1 
below outlines the study design.  
  
 Table 1.1:  In vivo study design 
Group Treatment and Dosage No. of Mice 
Control Saline 7 
MTH 0.3 0.3 mg/kg, 3x weekly 7 
MTH 0.6 0.6 mg/kg, 3x weekly 7 
 
 
After four weeks, the average tumor volume in saline treated mice was 876 mm3, 
whereas mice treated with 0.3 mg/kg MTH and 0.6 mg/kg of MTH was 632 mm3 and 447 
mm3 respectively (Figure 1.1B). The average tumor weights in the MTH treated mice 
were also decreased (0.56 g in 0.3 mg/kg; 0.34 g in 0.6 mg/kg) compared to saline 
treated mice (0.76 g) (Figure 1.1C). Inhibition of SP1 also led to an increase in PARP 
cleavage (Figure 1.1D) and increased cleaved caspase 3 staining (Figure 1.1E), 
indicating apoptotic cell death in these tumors. 
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Figure 1.1:  SP1 downregulation causes tumor regression 
MIA PaCa-2 cells injected subcutaneously and treated with saline or mithramycin for 4 
weeks. (A) Tumors explanted from saline, mithramycin 0.3 mg/kg, and mithramycin 0.6 
mg/kg (B) Tumor volume (C) Tumor weights (D) Tumors analyzed for apoptosis with anti-
cleaved PARP by western blot, and (E) cleaved caspase 3 by immunofluorescence. 
 
Consistent with our findings in vivo, treatment with MTH also caused UPR in pancreatic 
cancer cell lines MIA PaCa-2, S2-VP10, and S2-013 (Supplementary Figure 1.1A-D). 
Notably, using a UPR gene expression array, multiple genes were found to be 
dysregulated in MIA PaCa-2 cells treated with MTH for 1-6 hours (Supplementary Figure 
1.1A). In S2-VP10 and S2-013 cells, mRNA expression for the UPR regulator, GRP78, 
was upregulated in 1-3 hours, indicating the UPR was activated (Supplementary Figure 
1.1B). Additionally, protein expression from the UPR sensor, IRE1-α, and directly 
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downstream of a second UPR sensor, PERK, phosphorylated-eukaryotic initiation factor 
2α (p-EIF2α) were upregulated in a time-dependent manner (Supplementary Figure 
1.1C). Lastly, Downstream of IRE1-α activation, x box binding protein 1 (XBP1) has 
endoribonuclease activity, which splices 26 base pairs from the gene to create an active 
transcription factor, XBP-1s. MIA PaCa-2 cells demonstrate RNA splicing of the XBP1 
gene when treated with MTH from 1-24 hours (Supplementary Figure 1.1D). We further 
observed that while a short treatment (6 hours) with MTH elicited an “acute” response by 
triggering the UPR in the cancer cells, a longer treatment (24 hours) with MTH caused a 
complete breakdown of the ER stress machinery resulting in downregulation of UPR 
genes and causing “chronic” ER stress (Supplementary Figure 1.1B,C). 
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Supplementary Figure 1.1:  Mithramycin treatment activates the unfolded protein response 
(A) MIA PaCa-2 cells treated with 100 nM mithramycin for 1-6 hours. (B) S2-VP10 and  
S2-013 cells treated with 100 nM mithramycin for 0-24 hours. (C) Protein expression of 
UPR-related genes in MIA PaCa-2 cells treated with 100 nM mithramycin for 0-24 hours. 
(D) RNA splicing of XBP gene in MIA PaCa-2 cells treated with 100 nM mithramycin for 0-
24 hours, compared to 18s. 
 
Further, upon silencing SP1 in these cells using siRNA, we observed a similar induction 
of chronic ER stress in 24-48 hours (Supplementary Figure 1.2A-B). 
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Supplementary Figure 1.2:  siSP1 results in chronic ER stress 
MIA PaCa-2 cells transfected with siSP1 (A) RNA expression of 
UPR related genes at 24-48 hours. (B) Results in RNA splicing 
of XBP gene compared to 18s. 
 
SP1 downregulation leads to chronic ER stress via homeostatic disruption 
 
In order to elucidate how MTH causes chronic ER stress, we focused on the “master 
regulator” of UPR, GRP78. We first performed an activity assay of ER Stress Response 
Elements (ERSE), using a Cignal reporter assay (Qiagen). ERSE are the binding motifs 
that transcriptionally regulate UPR-induced genes. It has been reported that NF-Y, YY1, 
and Sp-family proteins, along with multiple ER stress-associated transcription factors all 
bind to the ERSE during a stress response59. Upon treatment with 100 nM MTH, the 
ERSE activity decreased to 0.771 RLU (relative luciferase units) compared to untreated 
cells (normalized to 1.0) in 8 hours (Figure 1.2A). After 24 hours of treatment, MTH 
treated cells showed a further decreased activity of 0.344 RLU compared to untreated 
cells (normalized to 1.0). Tunicamycin, a known ER stress inducer, was used as a 
positive control, and showed a robust increase in ERSE activity compared to untreated 
cells in 8 and 24 hours (2.500 and 4.861 RLU, respectively).  
 
To study if the decrease in ERSE activity was owing to decreased binding of SP1 to the 
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GRP78 promoter elements, we performed chromatin immunoprecipitation of SP1 on the 
GRP78 promoter. MIA PaCa-2 cells treated with 100 nM MTH showed a decrease in the 
% input of SP1 on the GRP78 promoter. Untreated cells had a % input of 3.177, 
whereas 6 hours of MTH treatment decreased to 1.348% and 0.239% in 24 hours 
(Figure 1.2B).  
 
 
Figure 1.2:  SP1 downregulation leads to chronic ER stress by deregulating the 
homeostatic mechanism 
Mithramycin treated MIA PaCa-2 cells analyzed for (A) ERSE dual-luciferase activity 
assay from 0-24 hours, and (B) ChIP of SP1 on the GRP78 promoter, from 0-24 hours. 
 
Tunicamycin treatment did not affect the SP1 binding on the GRP78 promoter after 6 
hours (Supplementary Figure 1.3A). 
 
 
Supplementary Figure 1.3:  Tunicamycin does not affect SP1 binding on 
the GRP78 promoter  
(A) MIA PaCa-2 cells analyzed for ChIP of SP1 on the GRP78 promoter, 
after 6 hours of treatment with tunicamycin compared to untreated cells.  
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ER stress initiates cell death via LMP  
 
To characterize how chronic ER stress, mediated by downregulation of SP1, results in 
cell death, we examined two common processes associated with apoptosis:  
permeabilization of lysosomal and mitochondrial membranes. We first studied the effect 
of chronic ER stress on lysosomal integrity.  
 
LMP leads to a release of cathepsins (lysosomal enzymes) into the cytosol. Treatment 
for 1 hour with 1 µM tunicamycin, a known ER stress inducer, resulted in a 5.92-fold 
increase in cathepsin B cytosolic activity in MIA PaCa-2 cells compared to untreated 
cells (Figure 1.3A). By downregulating SP1 with MTH for 1 hour, cathepsin B activity 
was 3.36-fold greater than untreated MIA PaCa-2 cells (Figure 1.3C).  
 
Additionally, using immunofluorescence detection, we saw a release of cathepsin B from 
the lysosomes upon treatment with TM (Figure 1.3B), and MTH (Figure 1.3D) for 6 
hours, as well as with other known ER stress inducers thapsigargin (TG) 
(Supplementary Figure 1.4A), and brefeldin A (BFA) (Supplementary Figure 1.4B).  
 
These findings unequivocally show that induction of chronic ER stress leads to LMP, 
indicated by a release of cathepsin B into the cytosol. Further, pre-treatment with a 
cathepsin B inhibitor, Ca074me, results in a rescue of viability after 24 hours (Figure 
1.3E). MIA PaCa-2 cells were also treated for 6 hours with tunicamycin and a cathepsin 
B inhibitor, which resulted in a reduction of cathepsin B release from the lysosomes 
compared to tunicamycin alone, as detected using immunofluorescence (Figure 1.3F). 
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Figure 1.3:  ER stress leads to a disruption in the lysosomal membrane 
MIA PaCa-2 cells analyzed for lysosome membrane permeabilization. (A) Cells treated 
with 1 μM tunicamycin and analyzed for cytosolic cathepsin B activity. (B) Cells treated with 
1 μM tunicamycin and stained with cathepsin B and lysotracker. Images taken at 60x. (C) 
Cells treated with 100 nM mithramycin and analyzed for cytosolic cathepsin B activity. (D) 
Cells treated with 100 nM mithramycin and stained with cathepsin B and lysotracker. 
Images taken at 60x. (E) Viability determined for cells treated with 100 nM mithramycin or 
1 μM tunicamycin, with and without a cathepsin B inhibitor, Ca074me. (F) Cells treated 
with 1 μM tunicamycin, with and without Ca074me detected by immunofluorescence. 
Images taken at 40x and 60x. 
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Supplementary Figure 1.4:  Other known ER stress inducers also result in LMP 
MIA PaCa-2 cells analyzed by immunofluorescence of cathepsin B and lysotracker after 
6 hours of treatment with (A) 100 nM thapsigargin (TG) (B) 1 µM brefeldin A (BFA). 
 
Since mitochondrial outer membrane permeabilization (MOMP) is also a commonly 
reported method of cell death, we sought to see if MOMP was another mechanism 
through which chronic ER stress led to cell death. MIA PaCa-2 cells were treated for 1 
and 6 hours with TM, TG, BFA, and MTH, and assayed for disruption of mitochondrial 
membrane potential (MMP). Based on our results, we can conclude that while TM had a 
minor disruption in MMP compared to the positive control, FCCP, the other inhibitors did 
not affect MMP within 6 hours of treatment (data not shown).  
Chronic ER stress results in a sustained accumulation of cytosolic calcium 
 
Calcium imbalance in the cytosol is a known inducer of ER stress in a cell, as calcium is 
one of the co-factors needed for protein folding. Sustained calcium release from the 
calcium stores in the cellular organelles, in response to a drug or noxious stimuli, 
eventually leads to cell death. Therefore, we measured the amount of cytosolic calcium 
in cells treated with multiple pharmacological inhibitors simulating chronic ER stress. 
Treatment of MIA PaCa-2, S2-VP10, and S2-013 cells with 100 nM MTH, 100 nM TG, 1 
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µM TM, and 1 µM BFA resulted in a sustained accumulation of cytosolic calcium 
between 6-24 hours, measured using calcium orange dye-based assay method (Figure 
1.4), as well as Fura-2 (data not shown). While 1 hour did not result in an appreciable 
amount of cytosolic calcium (data not shown), by 24 hours, we observed a sustained 
calcium accumulation in the cytosol.  
 
MIA PaCa-2 cells treated with SP1 siRNA and pharmacological inhibitors showed the 
following calcium levels at 24 hours:  untreated 100%, TG 143.5%, TM 131.0%, BFA 
192.0% (Figure 1.4A), MTH 136.0% (Figure 1.4B), siSP1 113.2% (Figure 1.4C). S2-
VP10 cells treated with pharmacological inhibitors showed the following calcium levels at 
24 hours:  untreated 100%, TG 131.9%, TM 177.6%, BFA 212.4% (Figure 1.4A), MTH 
126.0% (Figure 1.4B). S2-013 cells treated with pharmacological inhibitors showed the 
following calcium levels at 24 hours:  untreated 100%, TG 165.5%, TM 203.0%, BFA 
245.3% (Figure 1.4A), MTH 147.7% (Figure 1.4B).  
 
To determine if sustained accumulation of calcium was responsible for the cell death, we 
next used 10 µM of BAPTA (a calcium chelator) with each pharmacological inhibitor 
(data not shown).  While there was a decrease in cytosolic calcium upon treatment with 
BAPTA, the viability of the cells was unaffected (data not shown). This finding suggests 
that even though induction of chronic ER stress led to an accumulation of cytosolic 
calcium at 24 hours, cytosolic calcium did not precipitate the UPR. 
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Figure 1.4:  Chronic ER stress results in a sustained accumulation of 
cytosolic calcium 
MIA PaCa-2, S2-VP10, and S2-013 cells treated with (A) known ER 
stress inducers and measured cytosolic calcium after 24 hours of 
treatment, and (B) mithramycin and measured cytosolic calcium after 24 
hours of treatment, and (C) silenced with siSP1 measured cytosolic 
calcium after 24 hours of transfection. 
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DISCUSSION 
 
ER stress is a “condition” due to an accumulation of unfolded proteins in the ER. A 
variety of cellular insults can result in the accumulation of unfolded or incorrectly folded 
proteins52-54. In response to ER stress, a cell can initiate the UPR to adapt and survive, 
thereby re-establishing ER homeostasis. However, severe or chronic UPR can breach 
the threshold for survival, and lead to cell death. ER stress is an important mechanism, 
which has been implicated in various pathologies, and has the potential to be targeted 
therapeutically54, 55, 65, 66. There have been prior studies that have described UPR as a 
druggable mechanism in cancer because of the distinct metabolic requirements of 
cancer cells, and the activity of UPR compared to normal cells65, 66. As a result, it is 
important to understand how this mechanism works in cancer to find druggable targets, 
which can preferentially induce cancer cell death in cancer cells, while avoiding cellular 
adaptation and survival.  
 
Previous studies have determined that SP1 is necessary for an ER stress response59, 
and cancer cell survival15, 56. In order to restore ER homeostasis, active GRP78 
transcription is required. Interestingly, the RNA and protein expression of GRP78 
remained relatively unchanged, as the cells failed to regain homeostasis following SP1 
downregulation. Based on our data from the current investigation, in the absence of 
SP1, there is decreased binding of SP1 to the GRP78 promoter (Figure 1.2A). Without 
active transcription of GRP78, there is a breach in the threshold of stress that cells can 
handle, leading to cell death. By downregulating SP1 (Figures 1.1 and 1.2), we see a 
decrease in viability, in ERSE activity, and binding to the GRP78 and ATF6 promoters 
(ATF6 data not shown); whereas, tunicamycin did not affect SP1 binding 
(Supplementary Figure 1.3A). An increase in ERSE activity is one necessary step for a 
cell to re-establish homeostasis. Without SP1, GRP78 is not transcribed, and is unable 
to help the cells recover from ER stress and turn off the activated UPR. 
 
In previous studies, we have shown that triptolide works in two ways 1) it downregulates 
the substrate pool of O-GlcNAc, the modification of SP1, rendering it inactive; and 2) by 
causing chronic ER stress and cell death15, 19, 23. In our current study, we have shown 
that SP1 downregulation also causes chronic ER stress. To further characterize the cell 
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death mechanism induced by chronic ER stress, we studied lysosomal and 
mitochondrial cell death. Depending on the type of ER stress inducer, as well as the cell 
type, cancer cells can die by caspase-dependent or independent pathways upon LMP60. 
In AML and human monocytic leukemia/lymphoma, it has been shown that tunicamycin 
causes lysosome-mediated cell death, independent of the mitochondria52. In pancreatic 
cancer, bortezomib, a proteasome inhibitor, induces both LMP and MOMP67. Our group 
has published that triptolide results in LMP-mediated apoptosis, independent of 
MOMP22. However, triptolide in combination with TRAIL induces LMP and MOMP16. In 
the current study, we have shown that multiple ER stress inducers can result in LMP in 
PDAC (Figure 1.3), and initiate cell death, independent of MOMP. 
 
To further explore ER stress-induced cell death, we studied the effect of ER stress 
inducers on cytosolic calcium. Calcium regulation is essential for survival of every cell. 
The ER is a major storage site for calcium, which can be taken up via the SERCA pump. 
Conversely, calcium can be released from the ER, for example, to aid in cytosolic protein 
folding. Further, in autophagy, calcium is necessary for the fusion of the autophagosome 
and lysosome68. Our results clearly show that acute UPR observed in the first 6 hours, 
initiated by either known ER stress inducers or SP1 downregulation, does not lead to an 
accumulation of cytosolic calcium. However, upon onset of chronic/prolonged ER stress, 
there is an accumulation of calcium in the cell that leads to cell death in 24 hours (Figure 
1.4).  
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CONCLUSION 
 
This study underscores the importance of ER stress and understanding the complex 
balance of adaptation vs. cell death in pancreatic cancer. The current study identified 
SP1 and GRP78 as potential targets for future therapeutics in PDAC; discovered a 
protective role of SP1 in cancer; as well as further detailed ER stress response in cell 
death mechanisms. 
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METHODS 	
Cell Culture and Treatment 
Pancreatic cancer cell line, MIA PaCa-2 (obtained from ATCC) was cultured in DMEM; 
high glucose, supplemented with 10% FBS and 100 units/mL penicillin and 100 μg/mL 
streptomycin. S2-VP10 and S2-013 cell lines (a gift from Dr. Masato Yamamoto’s lab, 
University of Minnesota) were grown and propagated in RPMI, supplemented with 10% 
FBS, 100 units/mL penicillin and 100 μg/mL streptomycin. All cells were maintained at 
37°C in a humidified air atmosphere with 5% CO2. 
 
ON-TARGETplus SMARTpool human SP1 and GRP78 siRNA (Dharmacon) were used 
to silence expression of the respective genes in MIA PaCa-2 cells. Pool of 4 siRNA was 
used for all the above genes. Transfections were completed using DharmaFECT 
(Dharmacon) according to manufacturer’s instructions. The following drugs were used 
for this study:  mithramycin, tunicamycin, thapsigargin, brefeldin A (all from Sigma). 
 
Cell Viability Assay 
MIA PaCa-2 cells were seeded in a 96 well plate (7,000 cells/well) and allowed to 
adhere for 24 hours. Cells were transfected with 20 nM siRNA or treated with 100 nM 
mithramycin. Cell viability assays following siRNA or pharmacological inhibitors were 
performed using a WST-8 based cell cytotoxicity assay per the manufacturer’s protocol 
(Dojindo) and expressed after normalizing to untreated cells. 
 
Gene Expression Analyses  
RT-PCR:  RNA was isolated from the cells according to manufacturer’s instructions 
using Trizol (Invitrogen). Total RNA (2 µg) was used to perform real-time PCR using the 
Quantitect SyBr green PCR kit (Qiagen) according to the manufacturer’s instructions 
using Roche 480 real-time PCR system. All data were normalized to the housekeeping 
gene 18S (18s Quantitect Primer Assay; Qiagen). Quantitative RT-PCR primers for SP1, 
GRP78 (Qiagen). 
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Synthesized by Invitrogen/life technologies 
ATF6 F: GGAGTATTTTGTCCGCCTGC/ R: ACTGGGCTATTCGCTGAAGG 
XBP-u F: CAGACTACGTGCACCTCTGC/ R: GGCTGGTAAGGAACTGGGTC 
XBP-s F:CTGAGTCCGCAGCAGGTG/ R: GGCTGGTAAGGAACTGGGTC 
CHOP F: AGATGAGCGGGTGGCAGCGA/R: CCAGGCTTCCAGCTCCCAGC 
 
Western blotting:  Proteins from treated and untreated cell lysates were estimated using 
the BCA protein estimation assay (Thermo Scientific). Blots were probed for:  anti-SP1; 
anti-BiP; anti-IRE1a; anti-PERK; anti-phospho-PERK (Thr980); anti-eIF2a; anti-
phospho-eIF2a; anti-b-actin (all from Cell Signaling). 
 
Luciferase Reporter Assay for ERSE 
MIA PaCa-2 cells were seeded in a 24 well plate. Non-silencing and siSP1 were 
transfected in four wells each, and allowed to incubate for 15 hours. Cells were then 
transfected with the Cignal reporter plasmids for ERSE (Qiagen) and treated with 100 
nM MTH and 1 µM TM for 8 and 24 hours. At each time point, wells were washed with 
PBS, and 100 µL of passive lysis buffer was added per well. After 15 minutes of rocking 
in passive lysis buffer, plates were stored at -80°C until ready to read. The dual 
luciferase kit (Promega) was used to measure activity using a luminometer. Each 
sample was treated in duplicate for each plasmid (duplicates for the negative reporter 
and duplicates for the ERSE reporter).  	
Immunofluorescence 
MIA PaCa-2 cells were plated in chamber slides and incubated for 1-24 hours at 37°C. 
The slides were treated with 100 nM MTH, 1 µM TM, 100 nM TG, or BFA 1 µM; fixed 
with 2% paraformaldehyde, and permeabilized with CHAPS. The slides were incubated 
with 1:1000 dilution of rabbit polyclonal anti-cathepsin B antibody (Sigma) and a 1:1000 
dilution of Alexa 488-conjugated donkey anti-mouse IgG (Molecular Probes) for 
cathepsin B staining. The slides were mounted using Prolong Gold anti-fade with 4’,6-
diamidino-2-phenylindole (Molecular Probes). Immunofluorescence images were 
obtained on a confocal microscope (Nikon Eclipse Ti) with a 40-100x oil-immersion 
objective. EZ-C software was used to obtain images.  
	28		
Chromatin Immunoprecipitation  
MIA PaCa-2 cells were treated with 100 nM MTH for 6 and 24 hours. Samples were 
collected and processed per the manufacturer’s instructions (Pierce). GRP78 ChIP 
primer (GPH1026964(-) 01A; Qiagen) was used. 
 
Calcium Measurement:  Calcium orange-AM 
Cells were seeded in a white 96-well plate, and allowed to attach for 24 hours at 37°C, 
and then treated with various ER stress inducers, including MTH and siSP1. After 24 
hours of treatment, media was removed; cells were washed with phosphate-buffered 
saline (PBS), and loaded with 1.5 µL of 5 mmol/L Calcium Orange-AM (in 20% pluronic 
acid in DMSO) in serum free media for 1 hour. After incubation, the cells were washed 
with PBS three times, and fresh PBS was added for measurement of calcium. 
Luminescence measurements were obtained at 550 nM. A clear 96-well plate was used 
to determine viability, and the results were normalized to viability.   
 
Cathepsin B Assay 
Cells were seeded in a 6-well plate, and allowed to adhere for 24 hours. Cells were 
treated with 1 µM TM and 100 nM MTH for 1 hour each. To measure cytosolic cathepsin 
B activity, the cytosolic fraction was isolated using a cytosolic buffer (25 mM HEPES, 
120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4, 5 mM MgCl2, 2 mM EDTA, 2 mM ATP, 10 
mM DTT, pH 7.6) containing 20 µg/mL Streptolysin O for 20 minutes on ice. Cells were 
then washed without Streptolysin O, and incubated at 37°C for 20 minutes to selectively 
permeabilize the plasma membrane. The cells were then centrifuged at high speed to 
separate the cells and cytosol. Cathepsin B activity was determined using a cathepsin B 
selective substrate, N-carbobenzoxy-arginyl-arginine-naphthylamide (Bachem), as 
described by McDonald and Ellis69. Activity was expressed as units/mg protein in each 
sample.  
 
In vivo Study 
Athymic nude mice were injected with 106 MIA PaCa-2 cells suspended in Matrigel 
(Corning), subcutaneously in the right flank. Tumor size was measured weekly and mice 
	29		
were randomized when tumors reached an average of 250 mm3. Mice were randomized 
into saline, MTH 0.3 mg/kg, and MTH 0.6 mg/kg groups. MTH was administered 
intraperitoneally, three times per week. Mice were sacrificed when tumors reached 900 
mm3. The University of Minnesota Institutional Animal Care and Use Committee (IACUC) 
approved all procedures. 
 
Statistical Analysis 
Values are expressed as the mean +/- SEM. All in vitro experiments were performed at 
least three times. The significance between any two samples was analyzed by t-test, 
values of p<0.05 were considered statistically significant. 
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SUMMARY 
 
Background:  Chemoresistance is a major therapeutic challenge that plays a role in the 
poor statistical outcomes in pancreatic cancer. Unfolded Protein Response (UPR) is one 
of the homeostatic mechanisms in cancer cells that have been correlated with 
chemoresistance in a number of cancers including pancreatic cancer. 
 
Methods:  MIA PaCa-2, S2-VP10, and SU.86.86 pancreatic cancer cell lines were used 
for the following study. The significance of glucose regulatory protein 78 (GRP78), 
nuclear factor, erythroid 2-like 2 (NRF2) and ATP-binding cassette (ABC) transporter 
expression was established using the LSL-KrasG12D; LSL-Trp53R172H; Pdx-1-Cre (KPC) 
mouse model for mRNA and protein expression, as well as serum expression for 
GRP78. Genetic silencing of GRP78 and specificity protein 1 (SP1) was combined with 
chemotherapeutics in vitro to determine viability, ABC transporter activity, total cellular 
ATP and ATPase, antioxidant response activity, and reactive oxygen species (ROS) 
production. MIA PaCa-2 cells were injected into athymic nude mice subcutaneously, and 
treated with two doses of mithramycin (SP1 inhibitor), gemcitabine, or the combination of 
gemcitabine and mithramycin for four weeks. The effect of SP1 downregulation on 
GRP78 was determined, as well as the relative cell death in each group. 
 
Results:  In the current study, we showed that modulating GRP78, the master regulator 
of the UPR, could have a profound effect on multiple pathways that mediate 
chemoresistance. Our study showed for the first time that knockdown of GRP78 could 
diminish efflux activity of ABC transporters, and it could decrease the antioxidant 
response resulting in an accumulation of ROS. We also show that these effects could be 
mediated by the activity of SP1, a transcription factor overexpressed in pancreatic 
cancer. Thus, inhibition of SP1 negatively affects the UPR, deregulates the antioxidant 
response of NRF2, as well as ABC transporter activity by inhibiting GRP78-mediated ER 
homeostasis. 
 
Conclusion:  SP1 and NRF2 have been classified as non-oncogene addiction genes and 
thus are imperative to understanding the molecular mechanism of resistance. Our 
results show that the combination of gemcitabine and mithramycin attenuates 
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chemoresistance, resulting in more cell death and smaller tumor size in vivo.  These 
findings have clinical relevance as both SP1 and GRP78 are overexpressed in 
pancreatic cancer patients and increased expression of these proteins are indicative of 
poor prognosis. Understanding how these proteins may regulate the chemosensitivity of 
this aggressive cancer may pave the way for development of efficacious therapy for this 
devastating disease.  
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INTRODUCTION 
 
Pancreatic cancer is a devastating disease with relatively unchanged survival statistics 
for 70 years70. In 2017, it is estimated that 53,670 people will be diagnosed with 
pancreatic cancer, and 43,090 people will die from the disease70. FOLFIRINOX 
(oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil (5-FU) combination therapy) offers 
a slight survival benefit compared to gemcitabine alone, but only a small subset of 
patients can withstand the toxicity50, 71. One of the main reasons for the poor survival 
statistics in this disease is due to drug resistance to these standards of care, like 
gemcitabine, paclitaxel, and 5-FU.  
 
There are multiple mechanisms of chemoresistance employed by cancer cells. The 
unfolded protein response (UPR) contributes to chemoresistance, a homeostatic 
mechanism, which ameliorates stressful conditions to ensure cell survival. In order to 
survive the pressure created by the tumor microenvironment, including hypoxia and 
nutrient deprivation, tumor cells utilize the UPR pathways4, 33, 72, 73. Multiple components 
of the UPR have been linked to advanced tumor stage and chemoresistance in cancer32, 
74-76. For example, overexpression of protein disulfide isomerase family A member 5 
(PDIA5) in chronic myeloid leukemia shows increased resistance to Imatinib33. 
Overexpression of X box protein 1s (XBP1s) has been found in triple negative breast 
cancer, a resistant subset of breast cancer33, 77. XBP1s also correlates with higher tumor 
grade, chemoresistance, and shorter survival in lymphoma32.  
 
Glucose regulatory protein 78 (GRP78), the regulator of the UPR, has previously been 
correlated with poor patient prognosis in multiple cancers, including pancreatic cancer4, 
32, 73, 78, 79. Based on correlation studies and direct overexpression leading to 
chemoresistance, numerous proteins in the UPR pathway have been targeted with small 
molecules in hopes to attenuate chemoresistance33, 74, 75, 79. In spite of a generous body 
of literature correlating chemoresistance to expression of genes involved in UPR (Table 
2.1), there have been almost no studies to elucidate the mechanism(s) by which UPR 
contributes to chemoresistance.  
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Table 2.1:  UPR Activation in Multiple Cancers 
Cancer 
UPR 
Component Conclusion Described by Year 
Lung CHOP Correlates with high tumor stage and shorter survival Kim, KM. et al.
80 2012 
Breast GRP78, XBP1 Correlates with ER-negative 
Fernandez, PM. et al.77 
Scriven, P. et al.81 
2000 
2009 
Colon GRP78, CHOP 
Correlates with malignancy and tumor 
stage 
Rask, K. et al.82       
Xing, X. et al.83 
2000 
2006 
Gastric GRP78, GRP94 
Correlates with tumor size, invasion, 
metastasis, and stage 
Zheng, HC. et al.84 
Langer, R. et al.85 
2008 
2008 
Liver 
GRP78, 
ATF6, XPB1, 
HSP27, 
HSP70 
Correlates with histological grade, venous 
infiltration, CD147 expression 
Shuda, M. et al.86     
Luk, JM. et al.87      
Tang, J. et al.88 
2003 
2006 
2012 
Prostate GRP78 Correlates with survival, castration resistance, recurrence 
Pootrakul, L. et al.89 
Tan, SS. et al.90 
2006 
2011 
Kidney GRP78 Correlates with tumor grade, stage, invasion, metastasis, survival 
Fu, W. et al.91     
Kuroda, K. et al.92 
2010 
2011 
Skin GRP78 Correlates with metastasis, survival Zhuang, L. et al.93 2009 
Ovary GRP78 Correlates with malignancy Huang, LW. et al.94 2012 
Lymphoma 
XBP1, 
GRP94, 
IRE1, 
GADD34 
Correlates with tumor grade, resistance, 
survival 
Balague, O. et al.95 
Mozos, A. et al.96 
Boelens, J. et al.97 
2009 
2011 
2013 
Pancreas GRP78 Correlates with tumor stage, poor survival. Niu Z. et al78 2015 
 
Upregulation of the oxidative stress response pathway is another mechanism of 
decreasing chemotherapy-driven apoptosis. Management of oxidative stress decreases 
reactive oxygen species (ROS) accumulation in a cell, which in turn enhances 
detoxification and inhibits apoptotic cell death of tumor cells98, 99. The major transcription 
factor responsible for regulating oxidative stress response is Nuclear factor, erythroid 2-
like 2 (NRF2). NRF2 is downstream of the PKR-like endoplasmic reticulum kinase 
sensor in the UPR, and is one transcription factor that has been shown to regulate 
ABCC-subfamily expression100. NRF2 normally acts like a tumor suppressor, but over-
activation its antioxidant response elements (ARE) activity leads to cell survival of 
normal and malignant cells99-101. It has previously been reported that gemcitabine 
upregulates the NRF2 pathway, helping to mediate resistance4, 102. 
 
Another well-known mechanism of chemoresistance is through the ATP-binding cassette 
(ABC) transporter family. ABC-transporters drive the efflux of xenobiotics, including 
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chemotherapeutics. High transporter activity keeps intracellular chemotherapeutic 
concentrations low, thereby decreasing their overall effectiveness. The most common 
transporters involved in chemoresistance are BRCP (ABCG2), MDR1 (ABCB1), and 
MRPs (ABCCs)103-107.  
 
A previously published study from our laboratory showed higher GRP78 expression in 
tumor ducts compared to non-tumor tissue23. It was recently reported that GRP78 
correlates with poor prognosis and chemoresistance in pancreatic cancer78, 79. Further, it 
was shown that gemcitabine-resistant cell lines have higher GRP78 expression 
compared to gemcitabine-sensitive cell lines79. It has also been reported that patients 
with pancreatic cancer have an upregulation of ABC transporters, particularly ABCC3 
and ABCC5105, 108. However, it is unclear whether the ABC expression regulation 
correlates with PDAC tumor stages105, 108. 
 
Specificity protein 1 (SP1) regulates many biological functions, including cell growth, 
differentiation, survival, as well as tumor progression and metastasis15, 24, 26, 28, 56. Multiple 
studies have underscored the importance of SP1 in malignant tissues15, 24, 28. 
Interestingly, it has been reported in colon, gastric, pancreatic, and breast cancers that 
SP1 is overexpressed, whereas minimal to no SP1 expression is detected in normal 
differentiated cells15, 24, 28. We have recently published that upon downregulation of SP1, 
transcriptional regulation of GRP78 is adversely affected and cannot recover from 
chronic ER stress, which leads to cell death109.  
 
In this manuscript, we show for the first time that modulation of GRP78 expression by 
either overexpressing or silencing has a profound effect on a number of independent 
pathways that are responsible for chemoresistance. We further show that the effect of 
GRP78 modulation is mediated by the activity of SP1, a transcription factor that plays a 
significant role in maintaining ER homeostasis. Thus, inhibition of SP1 deregulates the 
antioxidant response of NRF2 as well as ABC transporter activity by inhibiting GRP78-
mediated ER homeostasis via the unfolded protein response. 
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RESULTS 
 
Based on studies listed in Table 2.1, GRP78 appears to correlate with tumor size, stage, 
malignancy, and chemoresistance. The correlation of GRP78 and chemoresistance was 
established just recently in pancreatic cancer. For our current study, we used multiple 
established cell lines. Supplementary Figure 2.1 below shows the mRNA expression of 
GRP78 (y-axis, also known as HSPA5), and NRF2 (x-axis), according to the publicly 
available RNAseq data on the Cancer Cell Line Encyclopedia.  
 
 
Supplementary Figure 2.1:  Comparison of GRP78 and NRF2 mRNA expression between 
multiple cell lines 
mRNA expression of GRP78 (y-axis) and NRF2 (x-axis) of multiple pancreatic cancer cell 
lines from CCLE RNAseq data. 
 
GRP78 expression correlates with tumor progression 
 
We found significantly increased GRP78 mRNA expression in tumor bearing mice 
(8.82e-6) compared to 1 month (7.76e-7) and 3 month mice (1.62e-6) (Figure 2.1A). 
Serum protein level of GRP78 was also significantly increased (0.53 ng/mL) compared 
to the non-tumor bearing controls (0.02 ng/mL) (Figure 2.1B). Further, we analyzed 
human patient serum for levels of GRP78, and found a similar increase in GRP78 
3.5 4.0 4.5 5.0 5.5
6
7
8
9
10
mRNA expression:  NRF2
m
RN
A 
ex
pr
es
si
on
:  
HS
PA
5
SW1990
PANC1
HPAC
SU8686
PANC0203
HPAFII
CAPAN1
CFPAC1
PANC0213
BXPC3
SUIT2
MIAPACA2
CAPAN2
PANC1005
ASPC1
	37		
expression (15 ng/mL) compared to healthy controls (below detection limit) (Figure 
2.1C). Consistent with our mRNA data, we looked at GRP78 protein expression in the 
KPC pancreata by immunofluorescence staining, and found an increase in the ductal 
expression of GRP78 in the tumor-bearing group compared to the non-tumor group 
(Figure 2.1D).  
 
 
Figure 2.1:  GRP78 expression correlates with tumor progression 
Analysis using KPC pancreata ranging from 1-9 months found that (A) GRP78 mRNA 
expression is overexpressed in pancreata with tumor compared to 1 or 3 month old KPC 
mice, and (B) GRP78 in serum from mice with tumors compared to mice without tumors was 
significantly greater. Serum from human patients also had elevated GRP78 compared to 
healthy controls (C). GRP78 protein expression (FITC) was found to be overexpressed in 
the ductal/pseudo-ductal regions in the tumor-bearing mice compared to mice without 
tumors (highlighted by arrows). Images were acquired at 20x magnification. (D). 
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Silencing GRP78 combined with chemotherapeutics increases cell death 
 
Three pancreatic cancer cell lines:  MIA PaCa-2, SU.86.86, and S2-VP10 were used to 
demonstrate the chemoresistance to relevant PDAC drugs (gemcitabine, paclitaxel, and 
5-FU). Figure 2.2A is a dose response curve for each cell line with the three drugs after 
48 hours of treatment. To determine if silencing GRP78 would diminish chemoresistance 
in the same cell lines, cells were transfected with siGRP78 and treated with gemcitabine, 
paclitaxel, or 5-FU for 24-48 hours. We found that combining chemotherapeutics (using 
greater than IC50 concentrations) with siGRP78 resulted in more cell death than silencing 
or drug treatment alone in 24 and 48 hours (Figure 2.2B, Supplementary Figure 2.1A-B). 
In addition to cell viability, apoptosis was detected using immunofluorescence by probing 
with a cleaved caspase 3 antibody. MIA PaCa-2 (Figure 2.2C, Supplementary Figure 
2.2A) and S2-VP10 (Supplementary Figure 2.2B) were transfected with non-silencing 
(NS) siRNA, NS + gemcitabine, siGRP78, or siGRP78 + gemcitabine for 24 hours. Our 
results show increased cleaved caspase 3 in siGRP78 + gemcitabine compared to 
gemcitabine or NS alone.  
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Figure 2.2 Silencing GRP78 combined with chemotherapeutics increases cell death.  
MIA PaCa-2, SU.86.86, and S2-VP10 cells were all treated with a dose response (0-100 µM) of 
gemcitabine, paclitaxel, and 5-fluorouracil for 48 hours (A). MIA PaCa-2 cells transfected with 
siGRP78 and treated with 400 nM gemcitabine, 50 nM paclitaxel, or 5 µM 5-FU for 24 and 48 
hours resulted in decreased viability compared to treatment or silencing alone (B). MIA PaCa-2 
cells transfected with NS siRNA (C-I), 400 nM gemcitabine (C-II), siGRP78 (C-III), or siGRP78 + 
gemcitabine (C-IV) for 24 hours. Cells were fixed and probed with a cleaved caspase 3 antibody 
for apoptosis, and images were acquired at 20x magnification.	
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Supplementary Figure 2.1:  Silencing GRP78 combined with chemotherapeutics decreases 
viability in pancreatic cancer cell lines 
(A) S2-VP10 cells transfected with siGRP78 and treated with 100 nM gemcitabine, 50 nM 
paclitaxel, or 5 µM 5-FU for 24 and 48 hours resulted in decreased viability compared to 
treatment or silencing alone. (B) Su.86.86 cells transfected with siGRP78 and treated with 400 
nM gemcitabine, 50 nM paclitaxel, or 5 µM 5-FU for 24 and 48 hours resulted in decreased 
viability compared to treatment or silencing alone.	
Supplementary Figure 1
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Supplementary Figure 2.2:  Silencing GRP78 combined with gemcitabine results in more cell 
death.  
(A) Quantitation of cleaved caspase 3 staining after MIA PaCa-2 cells were transfected with 
siGRP78 and treated with 400 nM gemcitabine 24 hours. (B). S2-VP10 cells transfected with NS 
siRNA (B-I), 100 nM gemcitabine (B-II), siGRP78 (B-III), or siGRP78 + gemcitabine (B-IV) for 24 
hours, and stained with cleaved caspase 3 for apoptosis, and the respective quantitation. Images 
were acquired at 20x magnification.	
 
Silencing GRP78 combined with chemotherapeutic compounds decreases ABC 
transporter activity in pancreatic cancer cells 
 
ABC-transporters are a known mechanism of chemoresistance. Our results showed 
numerous ABC transporters to be overexpressed in KPC tumors compared to 1 month 
KPC without tumors (Table 2.2). Further, using a dye-efflux assay, we found that 
gemcitabine and paclitaxel alone both increased the % efflux of cells (27.1% and 2.9%, 
respectively). Conversely, non-silencing (0.35-0.77%) and siGRP78 (0.43-0.88%) had 
minimal efflux activity. When MIA PaCa-2 cells were silenced with siGRP78 and treated 
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with gemcitabine, the % efflux decreased back to baseline (0.68%). siGRP78 and 
paclitaxel had a similar trend as gemcitabine, and the combination decreased the % 
efflux to 0.56% (Figure 2.3A).  
 
Table 2.2:  mRNA expression of ABC transporters in KPC mice 
 
1 month SEM 
3 month/pre-
tumor SEM Tumor SEM 
ABCA1 6.011E-07 2.69E-07 1.117E-06** 7.82E-07 1.125E-05** 1.41E-06 
ABCB1 4.539E-08 2.05E-08 3.096E-08** 1.63E-08 2.172E-06** 7.95E-07 
ABCC1 6.210E-07 3.60E-07 6.897E-07** 3.58E-07 5.478E-06** 1.25E-06 
ABCC2 4.731E-06 3.32E-06 3.076E-05 2.46E-05 5.852E-05 4.22E-05 
ABCC4 1.050E-07 5.19E-08 1.302E-07** 7.25E-08 2.941E-06** 7.21E-07 
ABCC5 8.264E-07 3.34E-07 1.167E-06* 4.71E-07 4.990E-06* 7.94E-07 
ABCG2 2.247E-07 6.90E-08 1.008E-05 7.53E-06 2.493E-06 1.29E-06 
*<0.001   ** <0.0001 
 
The dye efflux assay utilizes verapamil to effectively block transport, but also as a 
calcium channel blocker, blocks calcium channels. We next wanted to determine the 
effect on viability and calcium changes when blocking transporters using verapamil with 
and without siGRP78 or drugs. The combination of verapamil and drugs in MIA PaCa-2 
cells (Figure 2.3B, Supplementary Figure 2.3A) and S2-VP10 cells (Supplementary 
Figure 2.3B) decreased cell viability in 24 hours more than verapamil or drug alone. 
Next, we transfected MIA PaCa-2 cells with NS, siGRP78, NS + verapamil, or siGRP78 
+ verapamil for 1 and 6 hours, and stained cells with ER tracker and Fluo4 (calcium 
dye). Pearson coefficients were calculated for each group. After 1 hour, r ranged from 
0.3166 - 0.7254 (data not shown). However, in 6 hours NS had an r value of 0.8848; 
siGRP78 r = -0.1272; verapamil r = -0.5227; and siGRP78 + verapamil r = -0.4092 
(Figure 2.3C), indicating a negative correlation between calcium and ER tracker. 
 
ABC transporters are fueled by ATP. In order to determine how GRP78 (an ER resident 
protein) effectively decreases the ABC transporter activity, we silenced GRP78 and 
measured the total ATP and ATPase per condition described in MIA PaCa-2 cells. 
Results are expressed as relative luciferase units (RLU) per µg/mL protein. Gemcitabine 
alone increased ATP (4.62) as compared with non-silenced (1.74) and siGRP78 (3.26). 
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Gemcitabine with siGRP78 decreased the total ATP (4.02) compared to gemcitabine 
alone (Figure 2.3D). The amount of ATPase corresponds with the total cellular ATP. 
ATPase is expressed as µM phosphate per µg/mL protein. Gemcitabine had an increase 
in the ATPase (7.59e-4) compared to NS (0) or siGRP78 (2.80e-4) (Figure 2.3E), 
indicating that more ATP is being utilized. Gemcitabine with siGRP78 decreased the 
amount of ATPase compared to gemcitabine alone (3.94), indicating that less ATP is 
being utilized with the combination.  
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Figure 2.3:  GRP78 combined with chemotherapeutic compounds decreases ABC transporter 
activity in pancreatic cancer cells 
MIA PaCa-2 cells transfected with siGRP78 and treated with 400 nM gemcitabine or 50 nM 
paclitaxel for 8 hours +/- verapamil, and analyzed by flow cytometry (A). MIA PaCa-2 cells 
were treated with verapamil + chemotherapeutics for 24 hours to determine cell viability (B). 
Pearson coefficient was calculated for ER tracker and calcium co-localization in MIA PaCa-2 
cells transfected with siGRP78 and treated with 100 µM verapamil for 6 hours (C). MIA PaCa-
2 cells transfected with siGRP78 and treated with 400 nM gemcitabine for 24 hours to 
measure total ATP (D) and ATPase (E). Figures are representative of three experiments. 
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Supplementary Figure 2.3:  Verapamil combined with chemotherapeutic compounds decreases 
cell viability in pancreatic cancer cells 
(A) MIA PaCa-2 cells were treated with 5 µM 5-FU and 100 µM verapamil for 24 hours to 
determine cell viability. (B) S2-VP10 cells were treated with 100 µM verapamil and either 100 nM 
gemcitabine, 50 nm paclitaxel, or 5 µM 5-FU for 24 hours to determine cell viability. 
 
Silencing GRP78 combined with chemotherapeutic compounds decreases 
antioxidant response in activity in pancreatic cancer cells 
 
NRF2 is also an important mechanism of chemoresistance, by binding to the antioxidant 
response elements and transcribing detoxification genes, as well as some ABC-
transporters. We found that NRF2 mRNA expression is overexpressed in full tumor KPC 
pancreata (4.35e-5) compared to 1 month (3.33e-6) and 3 month pancreata without 
tumors (1.69e-5) (Figure 2.4A). In terms of activity, gemcitabine modestly increased the 
	46		
NRF2 activity in MIA PaCa-2 cells (1.71 RLU), as measured by a luciferase reporter of 
the antioxidant response elements (representative results shown). siGRP78 modestly 
decreased NRF2 activity (0.62 RLU), and when combined with gemcitabine (1.23 RLU), 
it decreases the activity closer to non-silenced cells (NS) (1.06 RLU) (Figure 2.4B). S2-
VP10 cells had a similar trend, but resulted in much more NRF2 activity. Gemcitabine 
increased the NRF2 activity (3632 RLU), siGRP78 was slightly higher than NS (1055 
RLU), and when combined with gemcitabine (1915 RLU), it decreases the activity closer 
to NS (320 RLU) (Figure 2.4C). Further, we observed that the total ROS detected with 
DCFDA dye was increased in the siGRP78 + gemcitabine compared to NS, siGRP78, or 
treatment alone in MIA PaCa-2 (Figure 2.4D) as well as in S2-VP10 (Figure 2.4E), 
indicating that the UPR-NRF2/ARE signaling is not able to decrease the amount of ROS 
being produced in the combination treatment. 
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Figure 2.4:  Silencing GRP78 combined with chemotherapeutic compounds decreases antioxidant 
response in activity in pancreatic cancer cells 
Analysis using KPC pancreata ranging from 1-9 months found that (A) NRF2 mRNA expression is 
overexpressed in pancreata with tumor compared to 1 or 3 month old KPC mice. MIA PaCa-2 cells 
transfected with siGRP78 and treated with 400 nM gemcitabine for 24 hours to measure ARE 
activity (B). S2-VP10 cells transfected with siGRP78 and treated with 100 nM gemcitabine for 24 
hours to measure ARE activity (C). ROS measurement of MIA PaCa-2 (D) and S2-VP10 (E) cells 
after 24 hours of treating with gemcitabine and siGRP78. 
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SP1 is required for ER homeostasis and affects chemoresistance in pancreatic 
cancer cells, similarly to GRP78 
 
We have previously shown that SP1 is required for ER homeostasis in pancreatic 
cancer109. MIA PaCa-2 (Figure 2.5A) and S2-VP10 cells (Supplementary Figure 2.4A) 
were treated with NS siRNA, NS + gemcitabine, siSP1, or siSP1 + gemcitabine for 24-48 
hours. We observed similar chemo-sensitivity as with siGRP78 when comparing cell 
viability with silencing SP1. In addition to cell viability, apoptosis of cells untreated vs. 
treated was detected using immunofluorescence by probing with a cleaved caspase 3 
antibody. Again, we observed similar results as with silencing GRP78, and found that 
combining siSP1 with drugs resulted in more cell death. (Figure 2.5B, Supplementary 
Figure 2.4B-C).  
 
Using a dye-efflux assay, we found that gemcitabine and paclitaxel alone both increased 
the % efflux of MIA PaCa-2 cells (26.9% and 3.0%, respectively). Conversely, non-
silencing (0.90-1.85%) and siSP1 (0.13-1.18%) had minimal efflux activity. The 
combination of siSP1 and gemcitabine decreased the % efflux towards baseline 
(5.83%), whereas siSP1 and paclitaxel modestly decreased efflux (0.7%) (Figure 2.5C).  
We also determined the total ATP and ATPase per condition in MIA PaCa-2 cells. 
Gemcitabine alone increased the ATP (4.62) compared to NS (1.72) and siSP1 (2.92) 
(Figure 2.5D). Gemcitabine with siSP1 decreased the total ATP compared to 
gemcitabine alone (3.23). The amount of ATPase corresponds with the total cellular 
ATP, in that gemcitabine had an increase in the ATPase (7.59e-4), indicating that more 
ATP is being utilized compared to NS (0) or siSP1 (1.41e-4) (Figure 2.5E). Gemcitabine 
with siSP1 decreased the amount of ATPase compared to gemcitabine alone (2.15e-4), 
indicating that less ATP is being utilized.  
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Figure 2.5:  SP1 is required for ER homeostasis and affects chemoresistance in pancreatic 
cancer cells, similarly to GRP78 
MIA PaCa-2 cells transfected with siSP1 and treated with 400 nM gemcitabine, 50 nM paclitaxel, 
or 5 µM 5-fluorouracil for 24 and 48 hours resulted in decreased viability compared to treatment 
or silencing alone (A). MIA PaCa-2 cells transfected with NS siRNA (B-I), 400 nM gemcitabine (B-
II), siSP1 (B-III), or siSP1 + gemcitabine (B-IV) for 24 hours, and probed with a cleaved caspase 
3 antibody for apoptosis. Images were acquired at 20x magnification. MIA PaCa-2 cells 
transfected with siSP1 and treated with 400 nM gemcitabine or 50 nM paclitaxel for 8 hours +/- 
verapamil, and analyzed by flow cytometry (C). ¨=0.07 •=0.08. MIA PaCa-2 cells transfected with 
siSP1 and treated with 400nM gemcitabine for 24 hours to measure total ATP(D) and ATPase(E). 
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Supplementary Figure 2.4:  SP1 is required for ER homeostasis and affects chemoresistance in 
pancreatic cancer cells, similarly to GRP78.  
S2-VP10 cells transfected with siSP1 and treated with 100 nM gemcitabine, 50 nM paclitaxel, or 5 
µM 5-fluorouracil for 24 and 48 hours resulted in decreased viability compared to treatment or 
silencing alone (A). (B) Quantitation of cleaved caspase 3 staining after MIA PaCa-2 cells were 
transfected with siSp1 and treated with 400 nM gemcitabine 24 hours. (C). S2-VP10 cells 
transfected with non-silencing siRNA (NS) (C-I), 100 nM gemcitabine (C-II), siSP1 (C-III), or 
siSP1 + gemcitabine (C-IV) for 24 hours, and stained with cleaved caspase 3 for apoptosis, and 
the respective quantitation. 
 
 
 
	51		
Inhibition of SP1 in vivo sensitizes tumors to gemcitabine therapy 	
In vivo subcutaneous injection of MIA PaCa-2 cells into athymic nude mice were injected 
with either saline, 0.3 mg/kg mithramycin (MTH; SP1 inhibitor), 0.6 mg/kg MTH, 50 
mg/kg gemcitabine (GEM), 0.3 mg/kg MTH and GEM, or 0.6 mg/kg MTH and GEM. Both 
combinations of MTH and GEM resulted in less tumor volume (0.3 MTH/GEM 304.0 
mm3; 0.6 MTH/GEM 307.9 mm3) than 0.3 mg/kg MTH (365.1 mm3), 0.6 mg/kg MTH 
(316.3 mm3), or GEM (407.2 mm3) (Figure 2.6A). Further, cleaved caspase 3 was 
increased in both 0.3 MTH/GEM (7.10) and 0.6 MTH/GEM (8.54) groups compared to 
single treatments (0.3 MTH 6.56; 0.6 MTH 5.91; GEM 5.24) and control (4.31) (Figure 
2.6B). 
 
	
Figure 2.6 Inhibition of SP1 in vivo overcomes gemcitabine-induced chemoresistance.  
MIA PaCa-2 cells injected subcutaneously into athymic nude mice, and treated with gemcitabine 
(50 mg/kg twice weekly), mithramycin (0.3 mg/kg or 0.6 mg/kg thrice weekly), or a combination of 
0.3 mithramycin and gemcitabine, or 0.6 mithramycin and gemcitabine. Tumor volume measured 
at the endpoint (A). Tumors were probed with a cleaved caspase 3 antibody and quantified with 
Image J. Images were acquired at 20x magnification (B). 
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Supplementary Figure 2.5 provides histological evidence that mithramycin sufficiently 
downregulates (A) SP1 and (B) GRP78.  
 
 
	
Supplementary Figure 5:  SP1 and GRP78 IHC 
MIA PaCa-2 subcutaneous tumors were stained for (A) SP1 and (B) GRP78. Each group 
compares Control (I); Gemcitabine 50 mg/kg (II); Mithramycin 0.3 mg/kg (III); Mithramycin 0.3 
mg/kg + Gemcitabine (IV); Mithramycin 0.6 mg/kg (V); and Mithramycin 0.6 mg/kg + 
Gemcitabine (VI). Images were acquired at 20x magnification.												
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DISCUSSION 
 
Various stressful conditions such as hypoxia, nutrient deprivation, pH changes or poor 
vascularization can be growth limiting for tumor cells, and thus activate the UPR4, 72, 73. 
As the cancer cells undergo rapid proliferation, the need for increased protein and other 
bimolecular synthesis contributes to an increased ER stress response in cancer cells4, 72. 
The ER is the main site for the translation of excess nutrition into metabolic and 
inflammatory responses. In tumor cells, ER stress may restore homeostasis and make 
the adjacent environment hospitable for tumor survival and tumor expansion, thus, is 
considered cytoprotective73, 110, 111. This makes the ER stress response one of the key 
survival responses in cancer.  
 
Chemoresistance in cancer has been shown to occur via a number of mechanisms. 
Some studies suggest that GRP78 membrane localization contributes to pro-proliferative 
pathways74, 75. While GRP78 membrane localization is a novel and interesting concept in 
cancer biology, our study finds that chemoresistance in pancreatic cancer cells can be 
mediated by an overexpression and increased activity of ABC transporter genes. Our 
data show that the expression of a number of genes in this superfamily correlates with 
the expression of GRP78 (Table 2.2). The ABC transporters typically efflux the 
chemotherapeutic drugs from the cells thereby minimizing their accumulation in the cells. 
These pumps are regulated by the ATP in the cells and are transcriptionally regulated by 
the transcription factor, NRF2, which binds to antioxidant response element in the 
promoter gene of these genes leading to their upregulation. Normal substrates for the 
ABC transporters include glutathione and glucuronide conjugates, which can be 
mediated through NRF2-ARE activity106, 107, which suggests that NRF2 and ABC 
transporters can alternatively work in tandem to promote chemoresistance. Further, Kras 
mutations have been shown to increase transcription and basal levels of NRF2 in 
cancer, which minimize intracellular ROS accumulation and maintain cancer cell 
survival99.  
 
ABC transporters have been an attractive target for many years, because of their role in 
chemoresistance112. A suggested strategy for battling chemoresistance is to decrease 
the efflux of the ABC transporters107. Verapamil is a first generation multidrug resistant 
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(MDR) modulator, whereas tariquidar and zosuquidar are third generation modulators, 
which have demonstrated fewer pharmacokinetic interactions with anti-neoplastics107, 113. 
Downregulation of GRP78 results in sensitizing the pancreatic cancer cells to multiple 
chemotherapeutic agents currently used in pancreatic cancer (Figure 2.2). Our results 
indicated that this was due to a decrease in the activity of the ABC transporters in these 
cells. Since ABC transporters depend on ATP hydrolysis, we estimated the ATPase 
activity in pancreatic cancer cells following GRP78 inhibition and drug treatment. GRP78 
has ATP binding sites to help in protein folding. We demonstrate that siGRP78 modestly 
increases the total cellular levels of ATP and ATPase, which could indicate this reduction 
is partly due to less GRP78 utilization of ATP. Additionally, we have shown that siGRP78 
decreases cellular viability, which is also an ATP-driven mechanism. Interestingly, our 
data also showed that gemcitabine with siGRP78 decreased the amount of ATPase 
compared to gemcitabine alone, which could indicate that less ATP is being utilized by 
the cell to drive ABC transporters. (Figure 2.3D). Similarly, inhibition of SP1 also showed 
increased sensitivity to gemcitabine by deregulation of ABC transporters (Figure 2.5C) 
and these effects could be observed both in vitro (Figure 2.5) and in vivo (Figure 2.6). 
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CONCLUSION 
 
There have been many efforts to target the UPR in recent years, including proteasome 
inhibitors, and inhibitors targeting GRP78, HSP90, PERK, and IRE1alpha32. GRP78, one 
of the regulators of the UPR, is an attractive target because it is responsible for 
maintaining homeostasis in the ER. Recently, a small molecule GRP78 inhibitor called 
IT-139, was shown to sensitize chemoresistant PDAC cells to gemcitabine79. Our 
previously published data shows that GRP78-mediated ER homeostasis is dependent 
on SP1 activity and inhibition of SP1 prevents the homeostasis and pushes the UPR to a 
chronic ER stress phase, leading to cancer cell death109. Our study is clinically relevant, 
because mithramycin (SP1 inhibitor) is undergoing clinical trials for lung, esophagus, 
breast, and GI cancers. Interestingly, SP1 and NRF2 have been recently described as 
non-oncogene addiction genes114, 115. Thus, understanding the interaction between 
multiple stress pathways (Unfolded Protein Response, Oxidative Stress) can contribute 
to development of better therapeutic targets to ameliorate the therapeutic resistance. 
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METHODS 	
Cell Culture and Treatment 
MIA PaCa-2 (obtained from ATCC) was cultured in DMEM; high glucose, supplemented 
with 10% FBS and 100 units/mL penicillin and 100 μg/mL streptomycin. S2-VP10 (a gift 
from Dr. Masato Yamamoto’s lab, University of Minnesota) and SU.86.86 (ATCC) were 
grown and propagated in RPMI, supplemented with 10% FBS, 100 units/mL penicillin 
and 100 μg/mL streptomycin. All cells were maintained at 37°C in a humidified air 
atmosphere with 5% CO2. 
 
ON-TARGETplus SMARTpool (pool of 4 siRNA) human SP1 (Dharmacon, Cat # L-
026959-00-0020) and GRP78 siRNA (Dharmacon, Cat # L-008198-00-0020) were used 
for silencing experiments. Transfections were completed using DharmaFECT 
(Dharmacon) according to manufacturer’s instructions. Evidence of silencing GRP78 and 
SP1 are provided in Supplementary Figure 6.  
 
Human HSPA5 siRNA (SMARTpool) Target Sequences   
GCGCAUUGAUACUAGAAA; GAACCAUCCCGUGGCAUAA; 
GAAAGAAGGUUACCCAUGC; AGAUGAAGCUGUAGCGUAU 
 
Human ON-TARGETplus Non-targeting siRNA #2 Target Sequence 
UGGUUUACAUGUUGUGUGA 
 
Human SP1 siRNA (SMARTpool) Target Sequences 
GCCAAUAGCUACUCAACUA; GAAGGGAGGCCCAGGUGUA; 
GGGCAGACCUUUACAACUC; CUACAGAGGCACAAACGUA 
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Supplementary Figure 2.6:  Evidence of silencing 
Protein from MIA PaCa-2 and S2-VP10 cells was used to verify silencing in 
vitro for (A) GRP78 and (B) SP1.  
 
KPC Tumor Analyses 
LSL-KrasG12D; LSL-Trp53R172H; Pdx-1-Cre (KPC) mice of various ages (1-9 months) were 
euthanized and pancreata were analyzed for mRNA and protein expression of GRP78, 
NRF2, and ABC transporters. Mice were sorted according to age and tumor status into 
non-tumor and full tumor groups; i.e. the 3 month KPC mice with tumors were placed in 
the tumor group (ranging from 3-9 months).  
 
Gene Expression Analyses  
RT-PCR:  RNA was isolated from the cells according to manufacturer’s instructions 
using Trizol (Invitrogen). Total RNA (2 µg) was used to make cDNA and perform real-
time PCR using the Quantitect SyBr green PCR kit (Qiagen) according to the 
manufacturer’s instructions using Roche 480 real-time PCR system. All data were 
normalized to the housekeeping gene 18S (Qiagen, Cat # QT00199367). Quantitative 
RT-PCR primers for SP1 (Qiagen, Cat # QT01870449), HSPA5 (GRP78) (Qiagen, Cat # 
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QT 00096404). 
 
ELISA 
KPC or human serum was used to analyze the GRP78 serum levels, using the Enzo 
ELISA kit, per manufacturer’s instructions. GRP78 antibody is immobilized in a pre-
coated plate. 100 µL of serum was pipetted in each well of a 96 well plate in duplicates, 
and allowed to bind overnight at 4°C. The following morning, the serum was removed 
and fresh GRP78 standards were prepared and pipetted in duplicates. 100 µL of biotin-
conjugated GRP78 antibody was added to each well, followed by 100 µL HRP-avidin 
secondary. Color formation was achieved using a TMB substrate for 30 minutes, and 
was detected at 450 nm using a microplate reader.  
 
Immunofluorescence 
Paraffin-embedded KPC mouse tissues were deparaffinized in xylene and then 
rehydrated in graded ethanol. After citrate antigen retrieval, tissues were blocked with 
Dako protein block, and incubated with primary (GRP78, Abcam ab21685) at 1:1000 
dilution. Slides were washed with PBS and incubated with Alexa Fluor 488 anti-rabbit 
secondary antibody for 1 hour. Slides were washed with PBS, and mounted with prolong 
gold with DAPI (Invitrogen).    
 
MIA PaCa-2 and S2-VP10 cells were plated in chamber slides and incubated for 1-24 
hours at 37°C. The slides were treated with 400 nM (MIA PaCa-2) or 100 nM (S2-VP10) 
gemcitabine; fixed with 2% paraformaldehyde. The slides were incubated with 1:1000 
dilution of rabbit polyclonal anti-cleaved caspase 3 antibody (Cell Signaling) and a 
1:1000 dilution of Alexa 488-conjugated donkey anti-rabbit IgG (Molecular Probes). The 
slides were mounted using Prolong Gold anti-fade with 4’,6-diamidino-2-phenylindole 
(Molecular Probes). Immunofluorescence images were obtained on a Leica DM6B with a 
20x objective. Cleaved caspase was quantified using Image J software. 
Immunohistochemistry 
Paraffin-embedded KPC mouse tissues were deparaffinized in xylene and then 
rehydrated in graded ethanol. Slides were steamed with pH 9 antigen retrieval (Dako). 
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Endogenous peroxidases were blocked with a 3% hydrogen peroxide solution. Tissues 
were then blocked with Dako protein block, and incubated with primary antibody 
overnight. Slides were stained with anti-SP1 (Cell Signaling, Cat # 9389) and anti-
GRP78 (Cell Signaling, Cat # 3177) at 1:200 dilutions. Slides were washed with PBS, 
incubated with secondary anti-rabbit antibody, conjugated to horseradish peroxidase, for 
30 minutes. Slides were washed again with PBS. Diaminobenzidine Peroxidase 
Substrate Kit (Vector Laboratories) was then added to slides. Primary antibody was 
omitted for negative controls. Slides were mounted with permount. Images were 
obtained on a Leica DM6B with a 20x objective. 
 
Cell Viability Assay 
MIA PaCa-2, S2-VP10 and SU.86.86 cells were seeded in a 96 well plate (7,000 
cells/well) and allowed to adhere for 24 hours. Cells were transfected with 20 nM non-
silencing siRNA (NS), siGRP78, or siSP1. Drug treatments used 400 nM (MIA PaCa-2) 
or 100 nM (S2-VP10) gemcitabine, 50 nM paclitaxel, or 5 µM 5-FU, unless otherwise 
specified. Cell viability assays following siRNA or pharmacological inhibitors were 
performed using a WST-8 based cell cytotoxicity assay per the manufacturer’s protocol 
(Dojindo) and expressed after normalizing to untreated cells. 
 
Dye Efflux Assay 
MIA PaCa-2 cells were plated in a 6 well plate. NS, siGRP78, and siSP1 were 
transfected in two wells each, and allowed to incubate for 15 hours. Cells were then 
treated with 400 nM gemcitabine or 50 nM paclitaxel for 8 hours. Cells were then gently 
scraped and were transferred equally into two flow cytometry tubes. In one set, NucBlue 
live dye was added, and incubated on ice. In the second set of tubes, NucBlue live dye 
was added, along with 100 µM verapamil, and incubated at 37°C for 30 minutes, and 
subsequently moved to ice. Flow cytometry was performed using the Pacific Blue and 
AmCyan. The percent of inhibition was calculated by:  (+Verapamil) – (-Verapamil). 
 
ATP Measurement 
MIA PaCa-2 and S2-VP10 cells were seeded in a 6 well plate. NS, siGRP78, and siSP1 
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were transfected in two wells each, and allowed to incubate for 15 hours. Cells were 
then treated with 400 nM (MIA PaCa-2) or 100 nM (S2-VP10) gemcitabine for 24 hours. 
Total cellular ATP was measured using the ENLITEN ATP assay system (Promega). 
Briefly, 1 µL trichloroacetic acid was added to 100 µL cell lysate to extract the ATP. Each 
sample was then neutralized with 900uL TAE (pH 8.0). A standard curve ranging from 
10-7 M to 10-11 M was prepared using the provided 10-7 M ATP standard. Luminescence 
was recorded for each sample and standard.  	
ATPase Activity Assay 
MIA PaCa-2 and S2-VP10 cells were seeded in a 6 well plate. NS, siGRP78, and siSP1 
were transfected in two wells each, and allowed to incubate for 15 hours. Cells were 
then treated with 400 nM (MIA PaCa-2) or 100 nM (S2-VP10) gemcitabine for 24 hours. 
Cells were lysed in lysis buffer and analyzed for ATPase per manufacturer’s instructions 
(Sigma). After assay incubation, plate was read at 620 nm for standards, blanks, and 
unknowns on a spectrophotometer.  	
ARE Reporter Assay 
MIA PaCa-2 and S2-VP10 cells were seeded in a 24 well plate. NS, siGRP78, and 
siSP1 were transfected in two wells each, and allowed to incubate for 15 hours. Cells 
were then transfected with the Cignal reporter plasmids for ARE (Qiagen) and treated 
with 400 nM (MIA PaCa-2) or 100 nM (S2-VP10) gemcitabine for 24 hours. Wells were 
washed with PBS, and 100 µL of passive lysis buffer was added per well. After 15 
minutes of rocking in passive lysis buffer, plates were stored at -80°C until ready to read. 
The dual luciferase kit (Promega) was used to measure activity using a luminometer. 
Each sample was treated in duplicate for each plasmid (duplicates for the negative 
reporter and duplicates for the ARE reporter).  	
Reactive Oxygen Species Assay 
MIA PaCa-2 and S2-VP10 cells were seeded in black, clear bottom 96 well plates. NS, 
siGRP78, and siSP1 were transfected in two wells each, and allowed to incubate for 15 
hours. Cells were then treated with 400 nM (MIA PaCa-2) or 100 nM (S2-VP10) 
gemcitabine, 50 nM paclitaxel, and 5 uM 5-FU for 24 hours. Media was removed and 
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replaced with 5 uM H2DCFDA/phenol-free media for 1 hour at 37°C. Cells were washed 
with PBS, and phenol-free media was replaced. ROS was measured at 5 minute 
intervals for 1 hour, with 492/517 ex/em filters. Results were expressed as ROS 
fluorescence per viability using a WST-8 cell cytotoxicity assay (Dojindo). 	
In vivo Study 
8-week-old athymic nude mice were injected subcutaneously (right flank) with 106 MIA 
PaCa-2 cells suspended in Matrigel (Corning). Mice were randomized when the average 
tumor size reached 135 mm3. Mice were randomized into the following groups:  1. saline; 
2. mithramycin 0.3 mg/kg; 3. mithramycin 0.6 mg/kg; 4. gemcitabine 50 mg/kg; 5. 
mithramycin 0.3 mg/kg + gemcitabine 50 mg/kg; and 6. mithramycin 0.6 mg/kg + 
gemcitabine 50 mg/kg. Saline and all mithramycin groups had 7 mice each; gemcitabine 
had 5 mice. Mithramycin was administered intraperitoneally three times per week. 
Gemcitabine was administered intraperitoneally 2 times per week. Tumors were 
measured weekly with a digital caliper. Mice were euthanized when tumors reached 900 
mm3. The University of Minnesota Institutional Animal Care and Use Committee (IACUC) 
approved all procedures. 	
Statistical Analysis 
Values are expressed as the mean +/- SEM. All in vitro experiments were performed at 
least three times. The significance between any two samples was analyzed by t-test, 
values of p<0.05 were considered statistically significant. 
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CHAPTER 3:  ER stress sensor, glucose regulatory protein 78 
(GRP78) is responsible for maintenance of “stemness” by 
regulating redox balance and DNA damage in pancreatic cancer 
 
Unpublished data 
Data and analysis performed by Patricia Dauer 
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SUMMARY 	
Background:  Endoplasmic reticulum (ER) stress and the unfolded protein response 
(UPR) signaling have been shown to be dysregulated in multiple cancer types. Glucose 
regulatory protein 78 (GRP78), the master regulator of the UPR is thought to play a role 
in proliferation, invasion, and metastasis in cancer. Cancer stem cells (CSCs) make up a 
crucial component of the tumor heterogeneity in pancreatic cancer, as well as other 
cancers. Even though UPR and CSCs have a role in multiple overlapping functions in 
tumors, there have been few studies connecting the concepts of CSCs and UPR. In the 
current study, we aimed to define what role GRP78 plays in the aggressive biology of 
pancreatic cancer. 
 
Methods:  Transcriptomic and proteomic analyses were conducted to compare S2-VP10 
control cells versus S2-VP10 shGRP78 cells. Cancer stem cell mRNA expression and 
key assays [colony formation, reactive oxygen species (ROS), invasion] were performed.  
 
Results:  We found that shGRP78 dysregulates multiple transcriptomic and proteomic 
pathways important in cancer. GRP78 downregulation decreases stemness and self-
renewal properties in vitro. In vivo studies resulted in delayed tumor initiation, as well as 
less tumor growth in the shGRP78 groups. Further, Downregulation of GRP78 results in 
fatty acid metabolism dysregulation.  
 
Conclusion:  Our studies show that downregulation of GRP78 disrupts multiple pathways 
that are key in proliferation, survival, fatty acid metabolism, and cell organization and 
biogenesis. Further, this study shows for the first time a connection to cancer stem cells, 
which are attributed to aggressive properties like chemoresistance and metastasis. 
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INTRODUCTION 	
Pancreatic cancer was a devastating disease 50 years ago, and it remains a devastating 
disease today. In 2018, it is estimated that 55,440 people will be diagnosed with 
pancreatic cancer, and 44,330 people will die from the disease in the United States1. 
Compared with the 20 most prevalent cancers in the United States, pancreatic cancer is 
the only type that has a five-year survival rate of less than 10% for all stages1. The only 
treatment option, which has shown to have curative potential, is surgical resection. 
However, less than 20% of patients are eligible for surgery upon diagnosis1. For those 
patients that surgery is an option, a number will have tumor recurrence within 5 years. 
The five-year survival rate after surgical resection can range up to 29%116-123. Suffice it to 
say, there is a need to understand the basic biology of pancreatic cancer further, in order 
to understand how to treat advanced stage patients better.  
 
One mechanism, which has been shown to be useful in oncogenic reprogramming, is 
the unfolded protein response (UPR). Endoplasmic reticulum (ER) stress and UPR 
signaling have been shown to be dysregulated in cancer33, 73, 124. ER stress is caused by 
a variety of physiological or xenobiotic pressures on the cell, like glucose deprivation, 
hypoxia, or chemotherapeutics. This in turn can disrupt the protein folding homeostasis 
in the ER, which activates an adaptive response, namely the UPR, which consists of 
three branches of unique downstream signaling to help recover from cellular stress. 
When inactivated, the three UPR branches are kept silent by close association with 
glucose regulatory protein 78 (GRP78), a mostly ER associated chaperone protein.  
 
The ER is also a major site for the synthesis of sterols and phospholipids, which are 
important membrane components. Maintenance of lipid homeostasis is important for 
normal cells, as well as cancer cells30, 125-127. It has been demonstrated that inhibition of 
GRP78 in breast cancer dysregulates lipid metabolism:  reducing fatty acid oxidation and 
resulting in an increase in cellular fatty acids128.  
 
This seemingly innocuous homeostatic mechanism can be hijacked by cancer cells to 
aid in tumor growth, migration, transformation, and angiogenesis33, 73. GRP78, the 
master regulator of the UPR, has been reported to be upregulated in multiple cancers74, 
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78, 124, 129. In pancreatic cancer, it was recently reported that GRP78 is also 
overexpressed 78. GRP78 is thought to play a role in proliferation, invasion, and 
metastasis in cancer74, 78. Additionally, there are a few studies showing that GRP78, and 
ER-resident protein, can translocate and be secreted74. In head and neck cancer, 
GRP78 is overexpressed, and it was reported that knocking down GRP78 decreased 
tumor initiation129.  
 
In vitro studies show that knocking down GRP78 in immortalized endothelial cells 
decreases proliferation, survival, and migration74. GRP78-/- mouse models are 
embryonic lethal40, 127. Heterozygous GRP78 mouse models are viable, but display an 
increase in ER stress proteins40, 41, 130. Studies have also shown that knocking down 
GRP78 decreases invasion and metastatic growth in vivo74. Another study using an 
inducible knockdown of GRP78 (Grp78f/f; Mx1-Cre) results in decreased hematopoietic 
stem cells, decreased lymphoid progenitors decrease viability, increased UPR and cell 
death130. These studies suggest that GRP78 may play an important role in the survival of 
normal stem cells, but its role in cancer stem cells (CSCs) is unclear. 
 
CSCs have been identified to play a major role in tumor recurrence because of their 
ability to promote tumor initiation, growth, metastasis, and chemoresistance124, 131-135. 
CSCs make up a crucial component of the tumor heterogeneity in pancreatic cancer, as 
well as other cancers. Even though UPR and CSCs have a role in multiple overlapping 
functions in tumors, there have been few studies connecting the concepts of CSCs and 
UPR. As the master regulator of the UPR, GRP78, few recent studies have suggested a 
role of GRP78 in maintaining the survival of CSCs136, 137. Additionally, Li et al. recently 
published that downregulation of inositol-requiring enzyme 1 alpha (IRE1α), one of three 
transmembrane sensors, resulted in a decrease of colon cancer stem cells138.  
 
In the current study, we aimed to define what role GRP78 plays in the biology of 
pancreatic cancer. We aimed to study this role, and determine if GRP78 is essential in 
maintaining the aggressive phenotype of pancreatic cancer by using a shGRP78 stable 
cell line. 
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RESULTS 	
GRP78 is an essential protein for maintaining the UPR, and has been shown to be 
important for cell survival30. This led us to inquire how GRP78 is important for cell 
survival, and why cancer stem cells seem to have more of it. For the following 
experiments, we created a stable shGRP78 clonal cell line with S2-VP10 cells.  
GRP78 knockdown decreases “stemness” and self-renewal properties in 
pancreatic cancer 
 
We first observed that the shGRP78 cells had a slower doubling cycle than the control 
cells. When we performed a proliferation assay by ECIS, we indeed found that the 
shGRP78 cells had a significant decrease in cell proliferation when compared to control 
cells (Figure 3.1A).  
 
Previous data published by Nomura, et al suggests that ER stress is important for 
cancer stem cells, because when sorted, CD133+ cells had more GRP78 and other heat 
shock protein (HSP)-family mRNA expression compared to CD133- cells13. In the current 
study, we found that shGRP78 cells had decreased CD133 mRNA expression in 
addition to significantly downregulated self-renewal genes (Figure 3.1B).  
 
Using an in vitro surrogate assay for stemness, we next performed a limiting-dilution 
colony formation assay. Control and shGRP78 cells were both plated in multiple dilutions 
ranging from 100,000 cells - 1 cell in a methylcellulose-based medium. After 6 days, the 
number of colonies in the 100,000 control cells was too many to count accurately, and 
was subsequently excluded. The number of colonies formed in each of the remaining 
groups was counted. shGRP78 cells had significantly fewer colonies formed than the 
control cells using both 10,000 and 1,000 cells (Figure 3.1C). No colonies were detected 
with 100, 10, or 1 cell.  
 
Nomura et al. has shown that CD133+ cells significantly induce invasion in vitro132. We 
showed that shGRP78 cells resulted in less CD133 expression (Figure 3.1B). To further 
demonstrate that GRP78 may play a role in maintaining the CSC and self-renewal 
phenotype in pancreatic cancer, we next looked at invasion. We used a Boyden 
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chamber assay with control or shGRP78 cells, to determine the number of invaded cells 
in 24 hours. We found that shGRP78 cells had a significant reduction in the number of 
invaded cells compared to the control cells (Figure 3.1D).  
 
 
Figure 3.1:  shGRP78 have decreased “stemness” and self-renewal phenotype 
Control and shGRP78 cells were analyzed for cell proliferation (A) and stemness and self-
renewal properties. (B) mRNA expression of CD133 and self-renewal genes (B) colony formation 
assay (C) cell invasion. Invasion images were taken with a 4x objective and counted with Image J 
software.   
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Tumor initiation and size are significantly reduced in GRP78 knockdown mice 
	
GRP78 knockdown has been reported to decrease tumor initiation in head and neck 
cancer129. Additionally, it has been shown to decrease proliferation and growth in other 
cancers40, 73, 128. To determine if GRP78 knockdown delays tumor initiation and growth, 
we injected 10,000 or 100,000 cells into athymic nude mice. We noted when each 
mouse formed a tumor, and tumor volume was measured weekly.  
 
When we injected 10,000 cells, 5/5 control mice formed tumors within 16 days, whereas 
only 2/5 shGRP78 mice formed tumors (Figure 3.2A). Based on this data, the tumor 
initiation frequencies were calculated, and 1/6214 control cells has probability to initiate 
a tumor, whereas only 1/45217 shGRP78 cells had the probability of initiating a tumor 
In the group that we injected 100,000 cells, we found that 5/5 control mice formed 
tumors within 11 days, and 4/5 shGRP78 mice formed tumors (Supplementary Figure 
3.1A). In addition to delayed tumor initiation, shGRP78 mice (both groups) had 
significantly smaller tumor volumes (Figure 3.2B, Supplementary Figure 3.1B) and 
significantly less tumor weight in the shGRP78-10,000 cell group (Figure 3.2C) 
compared to control mice after 4 weeks post-implantation. Even though the Control-
100,000 cells group had significantly greater tumor volumes than the corresponding 
shGRP78 group, many of the S2-VP10 tumors result in ascites and/or ulceration, 
thereby reducing the overall tumor weight upon necropsy (Supplementary Figure 3.1C). 
 
Examination of the H&E from the control and shGRP78 mice resulted in an 
unanticipated result of a pronounced accumulation of lipids in and around the tissues of 
the shGRP78 mice (Figure 3.2D). The tissues were stained with GRP78, in order to 
verify that there is indeed a reduction of GRP78 in vivo (Figure 3.2E). We also observed 
more apoptotic cells in the shGRP78 mice, when stained with TUNEL (Figure 3.2F).		
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Figure 3.2:  GRP78 knockdown results in delayed tumor initiation and smaller tumors 
Athymic nude mice were injected with 10,000 cells. (A) Tumor initiation was monitored daily for 
25 days. Tumor initiation frequency was determined based on total at 25 days. (B) Tumor volume 
was measured weekly for 36 days. (C) Tumor weights were noted at endpoint. (D) H&E of control 
and shGRP78 tumors. Control and shGRP78 tissues stained with (E) GRP78 and (F) TUNEL. 
Images were acquired with a 20x objective.  	
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Supplementary Figure 3.2:  GRP78 knockdown results in delayed tumor initiation and smaller 
tumors 
Athymic nude mice were injected with 100,000 cells. (A) Tumor initiation was monitored daily for 
25 days. (B) Tumor volume was measured weekly for 36 days. (C) Tumor weights were noted at 
endpoint.		
Downregulation of GRP78 leads to deregulated lipid metabolism 
 
Due to the unexpected finding of lipids in the H&E stained tissues, we decided to check 
the fatty acid metabolism in shGRP78 cells compared to controls. When GRP78 was 
inhibited in breast cancer, Cook et al. also found a change in lipid metabolism128. In that 
study, GRP78 inhibition reduced fatty acid oxidation and increased cellular fatty acids128. 
These effects could be caused by alterations in fatty acid uptake, lipid biosynthesis, or 
beta-oxidation. In the current investigation, we found multiple downregulated genes 
using a human fatty acid metabolism qPCR array (Figure 3.3A). Genes downregulated 
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included acetyl-CoA transferase, acyl-CoA dehydrogenase, acyl-CoA thioesterase, and 
acyl-CoA synthetase; glycerol kinase and glycerol dehydrogenase; lipase; protein 
kinases; and the solute carriers (fatty acid transporters). These in vitro results were 
consistent with mRNA from our subcutaneous tumors using the same fatty acid 
metabolism qPCR array (Supplementary Figure 3.2).  
 
Due to the fatty acid metabolism dysregulation, and based on the observations that 
shGRP78 results in slower proliferation, stemness, and invasion (Figure 3.1), we next 
supplemented cells with saturated (SFA) and unsaturated fatty acids (UFA), to see if 
shGRP78 cells would behave more like the control cells. It has been reported that SFAs 
induce ER stress, but UFAs can inhibit ER stress. We treated control and shGRP78 cells 
with palmitic acid (SFA), linoleic acid (UFA), or oleic acid (UFA) for 24 hours and 
determined cell viability, proliferation, and invasion ability. Supplementation of fatty acids 
did not significantly affect cell viability (data not shown), but increased proliferation and 
migration of shGRP78 cells (Figure 3.3B), and modestly increased the invasiveness of 
cells in vitro, determined using a Boyden chamber invasion assay (Figure 3.3C). 	
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Figure 3.3:  Downregulation of GRP78 results in deregulated fatty acid metabolism 
shGRP78 has dysregulated fatty acid metabolism genes in vitro (A). (B) The addition of fatty 
acids to shGRP78 cells slightly increased cell proliferation in 12 hours, and cell migration in 30 
hours, (C) Fatty acid supplementation modestly increases cell invasion using a Boyden chamber 
assay. Invasion images were taken with 5x objective and counted using Image J software.  	
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Supplementary Figure 3.2:  Downregulation of 
GRP78 results in deregulated fatty acid metabolism 
shGRP78 has dysregulated fatty acid metabolism 
genes in vivo. 	
Transcriptomic and proteomic analyses show GRP78 plays an important role in 
DNA damage and repair 
 
In order to elucidate the role that GRP78 and the UPR may play in CSCs and the 
aggressive phenotype of pancreatic cancer, we conducted a transcriptomic analysis of 
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our shGRP78 cells versus our controls. We found that many genes were significantly 
deregulated (Figure 3.4A). Supplementary Figure 3.3A lists the top 55 significantly 
deregulated canonical pathways. Among them are IL-1 signaling, which Nomura et al 
has reported in Molecular Cancer Research leads to epithelial to mesenchymal transition 
(EMT) and invasion in pancreatic cancer139. Drug resistance by drug efflux and 
xenobiotic metabolic signaling pathways were also deregulated, which supports the 
previous study in Chapter 2. Additionally, metabolic pathways including the pentose 
phosphate pathway were deregulated in the shGRP78 cells compared to controls. The 
top 25 dysregulated canonical pathways sorted by z-score are in Supplementary Figure 
3.3B. Among them are NRF2-oxidative stress signaling and growth factor signaling 
pathways. Further, the top deregulated genes are organized according to function in 
Figure 3.4B. There were 2971 genes dysregulated in shGRP78 cells compared to 
control, which are represented as 100 circles (100%). The number of colored circles is 
directly proportionate to the number of genes for that cellular function, in respect to the 
total number of genes. For example, 63/2971 genes are related to DNA damage 
response, which is 2.1% of total deregulated genes.  
 
Next, we conducted a qualitative mass spectrometry analysis of shGRP78 versus control 
cells. Though, we did not observe significant differences in the pathways dysregulated 
(data not shown). We next conducted a quantitative iTRAQ proteomic analysis between 
shGRP78 and control cells. Figure 3.4C are two heatmaps showing the upregulated 
(red) and downregulated (green) proteins of shGRP78 when compared to control cells.  
 
We found multiple canonical pathways dysregulated by GRP78 knockdown, including 
actin cytoskeleton signaling and protein ubiquitination. We also found significantly 
deregulated NRF2-mediated oxidative stress response, glutathione depletion, and G2/M 
DNA damage checkpoint regulation (Table 3.1). 268 proteins were involved in cell death 
and survival (p=3.91E-4-2.38E-13); 164 proteins involved in cellular assembly and 
organization (p=3.53E-4-3.99E-10); 198 proteins involved in cellular function and 
maintenance (p=5.35E-4-3.99E-10); 172 proteins involved in cell morphology (p=5.35E-4-
1.08E-8); and 161 proteins involved in cellular movement (p=2.86E-4-2.79E-7) (Table 3.2).  
 
Table 3.1:  Significantly deregulated pathways in shGRP78 cells 
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Pathway p-value 
Actin Cytoskeleton Signaling 4.82E-08 
Protein Ubiquitination  3.32E-06 
NRF2-mediated Oxidative Stress Response 6.14E-04 
Glutathione Depletion-Phase II Reactions 2.77E-02 
Cell Death 2.89E-02 
Cell Cycle:  G2/M Damage Checkpoint Regulation 2.93E-02 
 
Table 3.2:  Significantly deregulated molecular functions in shGRP78 cells 
Molecular Function p-value No. of Molecules 
Cell Death and Survival 3.91E-04 - 2.38E-13 268 
Cellular Assembly and Organization 3.53E-04 - 3.99E-10 164 
Cellular Function and Maintenance 5.35E-04 - 3.99E-10 198 
Cell Morphology 5.35E-04 - 1.08E-08 172 
Cellular Movement 2.86E-04 - 2.79E-07 161 
 
We identified multiple dysregulated proteins and categorized according to their cellular 
component (Figure 3.4D), molecular function (Figure 3.4E), and biological function 
(Figure 3.4F). We separated dysregulated proteins into cytoplasm (231), nucleus (250), 
ER (29), or membrane (282). The biological functions identified were:  cell differentiation 
(62), metabolic process (364), transport (148), cell death (32), cell organization and 
biogenesis (206). We further categorized according to molecular function:  protein 
binding (469), catalytic activity (237), DNA binding (109), and transporter activity (49). 
The top significantly deregulated genes/gene clusters are identified in Supplementary 
Figure 3.3C, where the q-value ranged from 0.001-0.05.  
 
	76		
 
Figure 3.4:  Transcriptomic and proteomic analyses show GRP78 plays an important role in DNA 
damage and repair 
Transcriptomic analysis was performed on shGRP78 versus control cells (A-B). (A) Volcano plot 
depicting the significantly deregulated genes (red=upregulated; green=downregulated). (B) Dot 
plot depicting the percentage of significantly deregulated genes by function. iTRAQ proteomic 
analysis was performed on shGRP78 versus control cells (C-F). (C) Heatmaps showing 
upregulated (red) and downregulated (green) genes. Deregulated genes were sorted according to 
(D) cellular component (E) molecular function, and (F) biological function. 
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Supplementary Figure 3.3:  Significantly deregulated canonical pathways 
Transcriptomic analysis was performed on shGRP78 versus control cells (A-B). (A) The top 55 
canonical pathways significantly deregulated. (B) The top 25 deregulated pathways sorted by z-
score. iTRAQ proteomic analysis was performed on shGRP78 versus control cells, and (C) 
depicts the top canonical pathways deregulated. 
 
GRP78 inhibition leads to deregulated redox balance in the cells leading to 
dysregulation of DNA damage and repair pathways 
 
Another attribute of pancreatic CSCs, which Nomura et al. described, is maintaining a 
low level of reactive oxygen species (ROS) production in CD133+ cells compared to 
CD133- cells133. This suggests that CSCs maintain a low level of ROS through the UPR-
	78		
Nuclear factor, erythroid-2-like-2 (NRF2) signaling activation. Interestingly, we found that 
shGRP78 cells have a higher ROS baseline compared to control cells (Figure 3.5A), 
indicating a loss of a functional prosurvival-NRF2 mechanism, that may result in more 
DNA damage, ROS production, and cell death, which we observed in our transcriptomic 
and proteomic analyses (Figure 3.4).  
 
 
Figure 3.5:  GRP78 knockdown leads to deregulated redox balance 
(A) ROS fluorescence of control and shGRP78 measured at 5-minute 
intervals over 60 minutes.  
 
Treatment with N-acetyl-cysteine rescues GRP78 knockdown cells from DNA 
damage and cell death. 
 
In order to determine if the cellular damage and DNA repair processes were the aspects 
of UPR that are important for maintaining “stemness” in pancreatic cancer, we next 
performed assays using an anti-oxidant, N-acetyl-cysteine (NAC). We found that 
treatment of 10 mM NAC for 24 hours lowered ROS levels, measured over 60 minutes, 
in comparison to control cells (Figure 3.6A). We also found that treating control and 
shGRP78 cells with 10 mM NAC for 24 hours rescued cell viability (3.9-fold and 5.3-fold 
over untreated control cells, respectively) (Figure 3.6B). Further, we observed that 
untreated shGRP78 had a 2.8-fold increase in caspase 3/7-mediated cell death when 
compared to untreated control cells. Whereas, treatment with 10 mM NAC for 24 hours 
rescued shGRP78 cells from caspase 3/7 mediated apoptosis (0.65-fold change 
normalized to control) (Figure 3.6C). 
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Figure 3.6:  Antioxidant, NAC, rescues shGRP78 from DNA damage-induced cell death 
Control and shGRP78 cells were treated +/- 10 mM N-acetyl-cysteine (NAC) for 24 hours. (A) 
ROS fluorescence was measured at 5-minute intervals over 60 minutes, (B) Cell viability after 24 
hours NAC treatment, and (C) Caspase 3/7-mediated activity after 24 hours of NAC treatment. 
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DISCUSSION 	
A number of events can occur once the UPR is activated, which can have various 
outcomes on a tumor cell. For example, nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB) activation leading to anti-apoptotic signaling; caspase 12 
activation and apoptosis; G1 arrest and apoptosis; G0 arrest and tumor cell dormancy; 
p38 activation and dormancy; or an increase in vascular endothelial growth factor 
(VEGF) secretion and angiogenesis, which leads to aggressive growth and metastasis73.  
 
ER stress has been implicated in and could be potentially having opposing roles during 
several different stages of tumor development. During early tumorigenesis and before 
angiogenesis, UPR activation can induce G1 arrest and activate p38, both of which can 
promote cell dormancy. If the pro-apoptotic branches of the UPR are also activated, 
cancer cells with mutations in the apoptotic machinery will be selected in order to evade 
cell death. ER stress also induces pro-survival NF-kB and inhibits p53-dependent 
apoptotic signals. In the event of a pro-survival UPR activation, ER stress can promote 
aggressive growth of these cancer cells by enhancing their angiogenesis73. 
 
In this study, we showed that knocking down GRP78 dramatically altered genes involved 
in DNA damage, oxidative stress signaling, and cell death (Figure 3.4).  We 
demonstrated the significant transcriptional and proteomic alterations ultimately affected 
cell proliferation. Further, we characterize for the first time, a connection with the UPR 
and stemness and self-renewal in pancreatic cancer (Figure 3.1). CSCs are capable of 
self-renewal, pluripotency, and metastasis, and remain elusive targets for current 
pancreatic ductal adenocarcinoma (PDAC) therapies. Thus, pharmacological targets of 
GRP78 or the UPR may be useful in combination with drugs that target rapidly 
proliferating cells, as well as the surrounding stromal cells.  
 
Knocking down GRP78 in pancreatic cancer seems to have a profound effect on the 
oxidative stress signaling, as well as fatty acid metabolism. ER stress can lead to 
lipogenesis and altered metabolism, whereas lipids and aberrant metabolism can lead to 
ER stress125. What is known is that cancer cells require more lipid production for 
survival126. Fatty acid synthase (FASN) is a multi-enzyme protein that catalyzes fatty 
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acid synthesis. FASN expression correlates with cancer progression, poor therapeutic 
response to gemcitabine, and survival (TCGA)126, 140. In addition, inhibiting FASN with 
orlistat has shown to decrease stemness in pancreatic cancer140.  
 
It has been reported that multiple cancer cell lines require unsaturated lipids126. In 
hypoxia (solid tumors), enzymatic reactions for de novo lipid synthesis are inactive, 
because they require oxygen126. As a result, cancer cells require exogenous unsaturated 
lipids, which can be acquired by desaturation of de novo fatty acids or by fatty acid 
uptake. Cells normally satisfy their fatty acid requirements from blood when triglycerides 
and low-density lipoproteins are hydrolyzed by lipoprotein lipase126. However, cancer 
cells are rapidly proliferating, and as a result, de novo lipid biogenesis provides most 
necessary lipids127. Inhibition of GRP78 has been shown to downregulate sterol 
regulatory element-binding protein (SREBP) transcription factors in breast cancer128. 
SREBP1 and 2 play an important role in regulating lipid metabolism, and regulating 
multiple metabolic genes [stearoyl-CoA desaturase (SCD1), FASN, acetyl-CoA 
carboxylase (ACC)]. Inhibiting SREBP can also result in decreased unsaturated lipids, 
resulting in cell death126. 	
 
 																
	82		
CONCLUSION 
 
Pancreatic cancer is characteristically an aggressive cancer type. One reason for the 
aggressive phenotype is because of the tumor heterogeneity; for example, PDAC has 
rapidly proliferating epithelial cells, cancer stem cells, and a dense surrounding stroma 
that creates a hypoxic environment. Interestingly, the UPR plays a role in each 
component, making PDAC exponentially more complicated. In our current study we have 
demonstrated that targeting the UPR, by downregulating GRP78, could be a method of 
targeting cancer stem cells, which could have promising clinical applications in treating 
PDAC.  
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METHODS 	
Cell Culture and Treatments 
S2-VP10 (a gift from Dr. Masato Yamamoto’s lab, University of Minnesota) cells were 
cultured in RPMI 1640 containing 10% fetal bovine serum and 1% 
penicillin/streptomycin. Cells were treated with 1 uM palmitic acid (Sigma), 10 uM linoleic 
acid (Sigma), or 400 uM oleic acid (Sigma) in 1% BSA. Cells were treated with 10 mM 
N-acetyl-cysteine (Sigma). 
 
Plasmid  
Four pGFP-C-shLenti-HSPA5 plasmids and one pGFP-C-shLenti-scrambled target were 
acquired from Origene (Cat # TL312303).  
 
Generation of Stable Cell Line 
S2-VP10 cells were transfected with one of four sh-GRP78 plasmids or scrambled sh 
plasmid (Origene). 1 µg/mL puromycin selection was applied after 48 hours post 
transfection. After verifying GFP expression, cells were collected and brought to a Flow 
Cytometry Core Facility. Cells were gated by GFP-positive expression, and sorted single 
cells into each well of a 96 well plate. Clones were propagated and maintained in RPMI 
with 1 µm puromycin. 
 
Transcriptomic Analysis 
Aliquots of RNA were derived from the qRT-PCR samples. Three control replicates and 
three shGRP78 replicates were analyzed. The RNA was quality tested using a 
Bioanalyzer 2100 (Agilent Technologies). cDNA was created by reverse transcription of 
oligo-dT purified polyadenylated RNA and fragmented, blunt-ended, and then ligated to 
barcoded adaptors. Then, the library was size selected, and the selection process was 
validated and quantified by capillary electrophoresis and qPCR, respectively. Samples 
were load on the HiSeq 2500 (Illumina Inc.) to generate around 25 million paired-end 
50bp reads for each sample. Quality control was conducted by FastQC 0.11.2 according 
to http://www.bioinformatics.babraham.ac.uk/projects/fastqc. The mean inner distance 
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was established using the insertion size metrics feature of Picard-tools. The resulting 
TopHat data served as input to other Cufflinks tools 2.2.0. Transcripts were also 
assembled using Cufflinks, with stipulating the reference transcriptome Homo sapiens. 
All cufflinks assemblies were merged with Cuffmerge. Differentially expressed genes 
(DEGs) were calculated with Cuffdiff and presented the data in terms of fragments per 
kilobase of transcript per million mapped reads (FPKMs). Visualization of data from 
Cuffdiff outputs was used CummeRbund v2.0.0141. Ingenuity Pathway Analysis (Qiagen) 
was used for pathway enrichment analysis.  
 
iTRAQ Proteomic Quantification 
Four control cell pellets and four shGRP78 pellets were prepared for iTRAQ MS/MS. To 
each cell pellet (each containing ~50 µg protein) 30 µL of dissolution buffer (0.5 M 
triethylammoniumbicarbonate (TEAB), pH 8.5) was added. Samples were denatured 
with 2% SDS, and reduced with 100 mM tris-(2-carboxyethyl) phosphine (TCEP). 
Samples were incubated for 1 hour at 60°C, and then 1 µL of 84 mM iodoacetamide 
solution was added, and incubated at 30°C in the dark. Promega Sequencing Grade 
trypsin was added to each sample, and then incubated at 37°C overnight. 8Plex iTRAQ 
reagents were prepared the following day by adding 50 µL isopropanol to each reagent. 
Each reagent was then transferred to one sample each. Sample-reagent mixtures were 
incubated at 2 hours at room temperature, and then the reactions were quenched with 
water, and combined into one tube. Sample was then vacuum dried, and washed three 
times with water.  
 
Gene Expression Analyses 
RT-PCR:  RNA was isolated from the cells according to manufacturer’s instructions 
using Trizol (Invitrogen). Total RNA (2 µg) was used to make cDNA and perform real-
time PCR using the Quantitect SyBr green PCR kit (Qiagen) according to the 
manufacturer’s instructions using Roche 480 real-time PCR system. All data were 
normalized to the housekeeping gene 18S (18s Quantitect Primer Assay; Qiagen). 
Primers for HSPA5 (GRP78), CD133, SOX2, OCT4, NANOG, GLI-1, Myc were acquired 
from Qiagen.  
 
	85		
Fatty Acid Metabolism Array (Qiagen) was used to study expression level of genes 
involved in fatty acid metabolism as described by manufacturer’s instructions.  
 
ECIS 
Proliferation was measured by Electric Cell-substrate Impedance Sensing (ECIS). 
Control and shGRP78 cells were seeded in 8W10E+ PET array with or without fatty acid 
supplementation (See Cell Culture and Treatments). Impedance (Z), capacitance (C) 
and resistance (R) were monitored for 48 hours by an ECIS Model Zϴ instrument 
(Applied BioPhysics Inc.) and normalized to Z0.  
 
Colony Formation Assay 
One million control and shGRP78 cells were prepared in 1 mL PBS. Cells were then 
serially diluted, and 100 µL of the diluted cells was added to the cell resuspension 
solution (R&D Systems). This mixture was added to 1.8 mL of methyl cellulose media, 
and plated in a 6-well plate with a blunt cannula.  
 
Reactive Oxygen Species Assay 
shGRP78 and control cells were seeded in black, clear bottom 96 well plates. Media was 
removed and replaced with 5 uM H2DCFDA/phenol-free media for 1 hour at 37°C. Cells 
were washed with PBS, and phenol-free media was replaced. ROS was measured at 5-
minute intervals for 1 hour, with 492/517 ex/em filters. Results were expressed as ROS 
fluorescence per viability using a WST-8 cell cytotoxicity assay (Dojindo). 
 
Cell Viability Assay 
shGRP78 and control cells were seeded in a 96 well plate (7,000 cells/well) and allowed 
to adhere for 24 hours. Cell viability assay was performed using a WST-8 based cell 
cytotoxicity assay per the manufacturer’s protocol (Dojindo) and expressed after 
normalizing to untreated cells. 
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Caspase 3/7 Activity 
shGRP78 and control cells were seeded in a white 96 well plate (10,000 cells/well) and 
allowed to adhere for 2 hours. Cells were then treated with 10 mM N-acetyl-cysteine for 
24 hours. Caspase 3/7 analysis was performed per manufacturer’s protocol (Promega).  
Caspase results were normalized to cell viability, which was plated in tandem.  
 
Boyden Chamber Invasion Assay 
Boyden chamber invasion inserts (Corning biocoat) were rehydrated for at least one 
hour in serum free medium at 37°C. Cells were plated into the inserts in serum free 
medium. The wells contained the attractant:  10% fetal bovine serum containing 
medium. After 24 hours, the top of the insert was washed with PBS, and inserts were 
fixed in methanol and stained with crystal violet. Membranes were analyzed using a light 
microscope. Cells were counted using Image J software. 
 
In vivo Study  
10,000 cells (control or shGRP78), and 100,000 cells (control or shGRP78) were 
resuspended in 50:50 PBS:matrigel mixture, and injected into the right flanks of athymic 
nude mice (5 mice per group). Tumor formation was monitored daily, and tumor volume 
was measure using a digital calipers. When the endpoint of the experiment was reached, 
mice were sacrificed, and tissues were resected and sent to pathology for embedding 
and preparation of H&E and unstained slides. All procedures were approved by the 
University of Miami Institutional Animal Care and Use Committee (IACUC). 
 
Immunohistochemistry 
Paraffin-embedded tissues were deparaffinized in xylene and then rehydrated in graded 
ethanol. TUNEL staining was completed per manufacturer’s instructions (Abcam, Cat # 
ab206386). Briefly, slides were permeabilized with a proteinase K solution, and covered 
with TdT equilibration buffer. Tissues were then labeled with a TdT labeling reaction 
mixture for 1.5 hours, and then a conjugate solution for 30 minutes. DAB solution was 
added for 15 minutes, and then slides were washed with water. Slides were 
counterstained with methyl green and mounted with permount. Images were obtained on 
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a Leica DM6B with a 20x objective. 
Immunofluorescence 
Slides were deparaffinized in xylene and rehydrated through graded ethanol solutions. 
Antigen retrieval was completed in a steamer using Reveal Decloaker (Biocare Medical) 
and blocked with Dako serum block. Primary antibody for GRP78 (Cell Signaling) was 
diluted 1:200 in Sniper (Biocare Medical). Alexa 555-conjugated donkey anti-rabbit IgG 
(Molecular Probes) secondary antibody was diluted 1:1000. The slides were mounted 
using Prolong Gold anti-fade with 4’,6-diamidino-2-phenylindole (Molecular Probes). 
Immunofluorescence images were obtained on a Leica DM6B with a 20x objective.  
Statistical Analysis 
Values are expressed as the mean +/- SEM. All in vitro experiments were performed at 
least three times. The significance between any two samples was analyzed by t-test, 
values of p<0.05 were considered statistically significant. 
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CHAPTER 4:  SPECIFICITY PROTEIN 1-MEDIATED ONCOGENIC 
SIGNALING AND TUMOR MICROENVIRONMENT CROSSTALK 
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SUMMARY 
 
Background:  Resident fibroblasts that contact tumor epithelial cells (TEC) are thought to 
become irreversibly activated as cancer-associated-fibroblasts (CAFs), which stimulate 
oncogenic signaling in TEC. 
 
Methods:  Transcriptome analysis of CAFs after 6 and 24 hours of triptolide treatment. 
Transforming growth factor-beta (TGF-β) and downstream effectors were analyzed with 
and without triptolide. Multiple markers of stromal activation were analyzed [vitamin A 
and lipid droplet expression, alpha smooth muscle actin (α-SMA) expression, 
extracellular matrix (ECM) secretion]. Finally, the effects of preventing TGF-β secretion 
were analyzed in TEC through specificity protein 1 (SP1) and SMAD activity.  
 
Results:  In this study, we evaluated the transcriptomic profiling conducted after 
treatment with triptolide revealed deregulation of the TGF-β signaling pathway in CAFs, 
resulting in an apparent reversal of their activated state to a quiescent, non-proliferative 
state. TEC exposed to media conditioned by drug-treated CAFs exhibited a decrease in 
oncogenic signaling as manifested by downregulation of the transcription factor SP1. 
This inhibition was rescued by treating TEC with recombinant TGF-β. 
 
Conclusion:  Given promising early clinical studies with Minnelide™, our findings 
suggest that approaches to inactivate CAFs and prevent tumor-stroma crosstalk may 
offer a viable strategy to treat pancreatic cancer. 
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INTRODUCTION 
 
Pancreatic cancer is one of the most devastating cancers with a dismal 5-year survival 
rate of less than 6% (www.cancer.gov)143. Recent studies suggest that the dense 
desmoplastic stroma, consisting of intense fibrosis, increased production of extracellular 
matrix (ECM), and proliferation of myofibroblast-like cells129, 144, contributes to the 
aggressiveness and chemotherapeutic resistance, thereby leading to poor survival. This 
fibro-inflammatory stroma, besides demonstrating multiple pro-cancerous features, 
contributes to an increase in tumor interstitial fluid pressure thus inhibiting delivery of 
anticancer therapies to the tumor cells12, 44, 45. However, stroma-targeted therapies have 
not been beneficial in terms of survival or prognosis48. An ideal therapeutic regimen for 
pancreatic ductal adenocarcinoma (PDAC) would thus be a combination of 
antitumorigenic drugs that are minimally toxic, and anti-stromal to deplete the dense 
stroma and/or disrupt its crosstalk with the tumor cells145, 146.  
 
The PDAC stroma consists of activated fibroblasts, also known as cancer associated 
fibroblasts (CAFs), immune cells, vasculature, and an abundance of ECM proteins5. This 
reactive milieu of cells modulates both tumor epithelial cells (TECs) and its 
microenvironment to promote tumor progression. CAFs secrete chemokines and 
cytokines that are pro-tumorigenic and help the tumor proliferate and metastasize. Whilst 
stromal cells do not exhibit the genetic transformations seen in malignant pancreatic 
cancer cells, they are altered by cytokines, and growth factors secreted by inflammatory 
cells and tumor cells147, 148. In the initial phases of tumor development, stroma production 
is stimulated by cancer-cell derived growth factors including transforming growth factor-β 
(TGF-β), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), and epidermal 
growth factor (EGF)149. These tumor-derived factors and immune cell derived factors 
activate the quiescent stellate cells in the pancreas and make them myofibroblast-like. 
During these transformations under the influence of the tumor, the activated stellate cells 
further transform to cancer-associated fibroblasts. In their activated state, CAFs secrete 
ECM components, primarily type I and III collagen, fibronectin, and proteoglycans. Till 
date it has not been elucidated if CAFs can revert to normal quiescent fibroblasts150, 151.  
 
Studies in our laboratory have shown that triptolide, a diterpene triepoxide from the 
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Chinese plant Tripterygium wilfordii, induces cell death in pancreatic cancer cells, and is 
effective in reducing tumor growth and locoregional spread in several complementary 
models of pancreatic cancer20. For ease of clinical application, we have developed a 
water-soluble prodrug, Minnelide™ for this compound9, 11, 14, 152-154. Mechanistically, we 
have demonstrated that Minnelide™ downregulates heat shock protein 70 (HSP70) via 
inhibition of the activity of the transcription factor specificity protein 1 (SP1), thereby 
leading to pancreatic cancer cell death15, 22. Our recent publications showed that in 
addition to being effective against the epithelial pancreatic cancer cells, Minnelide™ also 
depletes the stroma by preventing the synthesis of hyaluronan and collagen stabilization. 
Furthermore, treatment with Minnelide™ reduces the viability of CAFs isolated from the 
pancreatic tumors12. Our pre-clinical studies show that at a dose of 0.4 mg/kg, 
Minnelide™ is an effective cytotoxic compound that targets multiple pathways in a tumor 
cell. At this dose, Minnelide™ eliminates stromal cells and decreases ECM components 
like collagen and hyaluronan (HA), thereby relieving the pressure on blood vessels 
allowing them to be functional, which results in better drug delivery12. Minnelide™ has 
just completed the Phase I clinical trial against advanced gastrointestinal malignancies 
and is currently awaiting Phase II trials. The Phase I has yielded very encouraging 
results with significant tumor responses observed in terms of reduced tumor activity on 
PET-CT and many patients with partial response or stable disease155 (Manuscript under 
preparation). This Phase I trial revealed that the maximum tolerated dose for 
Minnelide™ is 0.67 mg/m2. This roughly translates to 0.2 mg/kg in mice. At this dose, 
Minnelide™ depletes the stromal ECM, resulting in relieving the interstitial pressure on 
the blood vessels and leading to better drug delivery12. 
 
In the current study, we performed an exhaustive transcriptome analysis on CAFs and 
determined that the profound effect of Minnelide™ on the pancreatic tumor stroma is 
due to inactivation of CAFs in the tumor. This further results in a low ECM production via 
suppression of the TGF-β signaling pathway in CAFs. Inactivation of CAFs lead to a 
decreased “cross-talk” between the tumor and the stroma, leading to decreased 
oncogenic signaling, suppressed tumor growth, and invasion. 
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RESULTS 
Transcriptomic analysis of Cancer Associated Fibroblast after triptolide treatment 
 
To study which pathways in CAFs were being downregulated by triptolide, we next 
conducted a transcriptome analysis based on RNA-Seq. Cell lines CAF-1, CAF-5, and 
CAF-7 were either untreated or treated with triptolide (100 nM) for 6 hours or 24 hours. 
All samples had around 25 million paired reads with over 90% mapped uniquely 
mapped142. A total of 3859 differentially expressed genes (DEGs) were identified 
between control group and triptolide 24 hour group with a false discovery rate (FDR) of 
0.05 (Figure 4.1A-B). To further analyze the pathways that are deregulated by triptolide, 
we conducted pathway enrichment analysis and found that most significantly 
downregulated pathways were the RAR/RXR signaling pathway and TGF-β signaling 
(Figure 4.1C). Interestingly, RAR/RXR pathway is a retinoic acid (RA) stimulated 
pathway. In the presence of RA, which is a morphogen derived from vitamin A, RA 
translocates to the nucleus and stimulates the RAR/RXR to bind to their response 
elements (RARE), resulting in transcription of genes that regulate differentiation, 
survival, and TGF-β secretion. Our analysis showed that several genes in the TGF 
pathway (Supplementary Figure 4.1B) and RAR/RXR pathway142 were being 
differentially regulated. 
 
IPA analysis showed that TGF-β signaling pathway was significantly downregulated in 
CAFs (Figure 4.1D). Furthermore, the downstream genes of TGF-β signaling pathway 
were also downregulated in triptolide treated group (Figure 4.1E-F). Interestingly, in the 
TECs, these pathways were not among the top significant pathways that were 
deregulated (data not shown).  
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Figure 4.1:  Transcriptome analysis of triptolide treated CAFs 
Differentially expressed genes in CAFs before and after triptolide treatment were shown in 
heatmap (A). Principal component analysis showed three distinct groups of all samples that 
correlate to different treatments (B). Pathways that are significantly deregulated in 24 hours 
triptolide treatment samples were shown as bar plot (C). Visualization of TGF-β pathway in 
response to triptolide treatment in CAFs. Green label means downregulated genes and red label 
means upregulated genes (D). GSEA indicated obvious suppressive role of triptolide on TGF-β 
pathway downstream genes’ expression (E). Heatmap of TGF-β pathway downstream genes’ 
expression before and after triptolide treatment. Red means high expression and blue means low 
expression (F). 
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Supplementary Figure 4.1:  Analysis of the RNAseq data showed 
the TGF-β pathway and RAR/RXR (not shown) to be the top two 
deregulated pathways in CAFs after treatment with Minnelide. 
 
Triptolide downregulated the TGF-β pathway in CAFs at a sub-lethal dose  
 
It is well known that upon activation, the stromal cells, specifically fibroblasts, secrete 
TGF-β. Our results confirmed this (Figure 4.2A-B). Since our transcriptomics analysis 
was done at a dose of 100 nM triptolide, we next studied the effect of low dose of 
triptolide on the TGF-β signaling. We treated the CAFs with a very low dose of 25 nM 
triptolide and analyzed all the components of the TGF-β pathway. Our study showed that 
the autocrine TGF-β signaling pathway in the CAFs was downregulated even at 25 nM 
triptolide. The expression of TGF-β was significantly decreased both at the RNA level 
(Figure 4.2C) as well as secretion level in both cells and supernatant (Figure 4.2D-E). 
Additionally, effectors of TGF-β pathway (SMAD2, 3, 4) were downregulated both at the 
RNA (Figure 4.2F) and protein level (Figure 4.2G). In addition, several other genes that 
were directly being regulated by the TGF-β signaling were also downregulated (Figure 
4.2F). The expression and secretion of the TGF-β, as well as all its components that 
were decreased by triptolide treatment were rescued when treated with recombinant 
TGF-β (Figure 4.2G-F). 
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Figure 4.2:  Triptolide downregulated TGF-β pathway in the CAFs 
Activated pancreatic stellate cells (PSCs) produced more active as well as total TGF-β compared 
to the TECs in culture supernatant (A) as well as in the cell lysate (B) as seen by the ratio of the 
active:total TGF-β. Treatment with 25 nM triptolide (sub-lethal) decreased mRNA expression (C) 
as well as active:total TGF-β in hPSC supernatant (D) as well as in cell lysates (E). mRNA 
expression of several genes in the TGF-β pathway were downregulated by triptolide treatment of 
activated PSC. This was rescued by addition of recombinant TGF-β (F). Triptolide treatment also 
downregulated the activity of SMAD2 and SMAD3 proteins as seen by decreased 
phosphorylation in western blot. This was rescued by addition of recombinant TGF-β (G).  
* signifies p<0.05 in control vs. triptolide treatment; # signifies p<0.05 in triptolide treated vs. TGF-
β + triptolide treated samples. 
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Downregulation of TGF-β pathway in CAFs reverted them from activated to 
inactivated state 
 
Activation of pancreatic stellate cells (PSCs) is characterized by loss of Vitamin A 
droplets in these cells and a subsequent increase in α-SMA expression. Thus, an 
increase in Vitamin A and lipid droplet accumulation in the fibroblast as well as a loss of 
α-SMA would indicate an inactivation of CAFs. We observed that treatment with lose 
dose triptolide decreased proliferation of CAFs, without affecting their viability (Figure 
4.3A).  
 
To study if this was due to “inactivation” of CAFs, we next analyzed the vitamin A 
droplets in these cells after treatment with triptolide. Our results showed that treatment 
with triptolide increased vitamin A accumulation (seen by monitoring fluorescence at 338 
nm) in CAFs. Interestingly, upon treatment with TGF-β in the presence of triptolide, the 
vitamin A fluorescence decreased to that observed in untreated cells (Figure 4.3B). This 
indicated that TGF-β was capable of reverting the triptolide-induced inactivation. This 
was further supplemented by our IPA analysis of the RAR/RXR pathway. We observed 
an increased expression of retinol binding protein (RBP) in our triptolide treated CAFs142. 
RBP is required for stabilization of retinol in the cells, thus, this further conformed to our 
hypothesis that triptolide was indeed inactivating the CAFs, resulting in accumulation of 
vitamin A. To confirm this observation further, we next performed an Oil Red staining on 
the CAF cells. We observed an increased Oil Red stain in the triptolide treated CAFs, 
which decreased upon treatment with TGF-β (Figure 4.3C).  
 
α-SMA is a classic marker for activation of PSCs. When in their quiescent state, PSCs 
do not express α-SMA. However, upon activation, this protein is upregulated. Treatment 
of CAF cells with triptolide decreased the α-SMA+ cells as seen by flow cytometry 
(Figure 4.3D). 
 
	97		
 
Figure 4.3:  Downregulation of TGF-β pathway in CAFs by triptolide reverts them from activated 
to inactivated state 
Treatment of TEC (KPC001) with conditioned media from CAF7 treated with 25 nM triptolide 
decreased proliferation rate of KPC001 as measured by ECIS (A), resulted in vitamin A 
accumulation as observed by change of fluorescence at 338 nm (B) and lipid droplet 
accumulation by oil red staining (C). Further, analysis of α-SMA expression by flow cytometry 
showed a decrease in the intensity of staining indicating an inactivation of CAF cells in the 
presence of triptolide (D).  
* signifies p<0.05 in control vs. triptolide treatment; # signifies p<0.05 in triptolide treated vs. TGF-
β + triptolide treated samples. 
 
To study if treatment with triptolide is affecting the other functions of CAFs as well, we 
next analyzed their ECM secretion. Our results showed that treatment with 25 nM 
triptolide decreased the secretion of fibronectin (Figure 4.4A), periostin (Figure 4.4B), 
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collagen (Figure 4.4C), hyaluronic acid (Figure 4.4D), MMP2 (Figure 4.4E), and MMP9 
(Figure 4.4F). Further, treatment with TGF-β reverted this decreased ECM production 
(Figure 4.4G-H).  
 
 
Figure 4.4:  Treatment with triptolide decreased ECM secretion by CAFs 
Treatment with 25 nM triptolide decreased the secretion of fibronectin (A), periostin (B), collagen 
(C), hyaluronic acid (D), MMP2 (E), and MMP9 (F). Further, treatment with TGF-β reverted this 
decreased ECM production (G, H); * signifies p<0.05 in control vs. triptolide treatment; # signifies 
p<0.05 in triptolide treated vs. TGF-β + triptolide treated samples. 
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Decreased TGF-β signaling in CAFs affected oncogenic signaling in tumor 
epithelial cells 
 
It is well established that the tumor-stroma crosstalk is involved in tumor progression and 
metastasis. Since our data indicated that triptolide decreased the TGF-β signaling in the 
CAF cells and also induced inactivation, we next studied the effect of this inactivation on 
the TEC. Our previously published data showed that SP1 was one of the transcription 
factors that was overexpressed in pancreatic cancer, and this in turn upregulated the 
anti-apoptotic pathways and proteins like NF-κB pathway and HSP70. To study if the 
decreased TGF-β from the “inactivated” CAFs decreased these pathways, we next set 
used conditioned media from activated PSC cells (+/- triptolide) and added it to MIA 
PaCa-2 cells. In a parallel set, we added 10 ng/mL TGF-β to the MIA PaCa-2 cells with 
conditioned media from 25 nM triptolide treated PSC cells.  
 
A dual luciferase reporter assay for SMAD showed that the conditioned media from 
triptolide treated PSC cells downregulated the SMAD transcriptional activity, which was 
rescued in the presence of TGF-β (Figure 4.5A). Since SMAD transcriptional activity 
leads to transcription of SP125, 156, 157, we next tested the SP1 gene expression and 
activity. Our results showed that SP1 mRNA expression was downregulated in the set 
with conditioned media from 25 nM triptolide. This expression was subsequently rescued 
upon adding TGF-β to the MIA PaCa-2 cells (Figure 4.5B).  
 
We next studied the effect of CAF inactivation on SP1 DNA binding and transcriptional 
activity. Our results showed that in the presence of conditioned media from the 25 nM 
triptolide treated PSC, SP1 binding was significantly decreased (Figure 4.5C), indicating 
that CAF inactivation led to inhibition of transcriptional activity as well. Treatment with 
TGF-β reverted the SP1 DNA binding, confirming that this inhibition of DNA binding was 
mediated via downregulation of TGF-β secretion by the PSCs. Our previously published 
data show that in the TECs, SP1 downregulation inhibits anti-apoptotic proteins like NF-
κB and HSP70.  
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To study if inactivation of PSCs also led to this phenotype we studied the HSP70 and 
NF-κB gene expression after treating cancer cells with conditioned media from 25 nM 
triptolide. Our results showed that MIA PaCa-2 cells treated with conditioned media from 
PSCs plus triptolide downregulated p50 and p65 expression, and adding TGF-β 
upregulated expression, when compared to untreated PSC conditioned media (Figure 
4.5D). 
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Figure 4.5:  Downregulation of TGF-β in CAFs inhibits oncogenic signaling in TECs 
Treatment of TEC (MIA PaCa-2 or S2-VP10) with conditioned media from activated PSC treated 
with 25 nM triptolide decreased SMAD transcriptional activity as seen by dual luciferase assay 
(A). This resulted in decreased SP1 expression in the TECs (B). Further, DNA binding ability of 
SP1 was inhibited (C). Expression of genes downstream of SP1 like HSP70, HSF1, and 
components of NF-kB pathway (RELA and NFKB1) were also downregulated. These were 
rescued upon addition of recombinant TGF-β (D).  
* signifies p<0.05 in control vs. triptolide treatment; # signifies p<0.05 in triptolide treated vs. TGF-
β + triptolide treated samples. 
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DISCUSSION 
 
Pancreatic tumors are characterized by a robust desmoplastic stroma; a significant part 
of which is comprised of myo-fibroblast like cells. The origin of these cells remains 
unclear but a substantial part of these cells are derived from PSCs. These cells are very 
similar to those found in the liver (hepatic stellate cells, HSC), which have been well 
studied in context of liver injury. In a normal pancreas, the PSCs are a quiescent 
population typically characterized by the presence of a large amount of vitamin A 
droplets or retinol158-160. Exposure of PSCs to UV light at 300-338 nm elicits a transient 
blue-green fluorescence that can be quantitated147. Upon inflammatory stimulation from 
the environment, these cells become activated, “losing” their retinoid containing lipid 
droplets and become myo-fibroblastic, secreting α-SMA. Even though a number of 
studies have been focused on the biology of the pancreatic stellate cells and their 
activation, the mechanism of loss of retinoids has not been studied in PSCs as they 
have been studied in HSCs. In HSCs, activation leads to the metabolism of retinol to 
retinoic acid, which acts as a ligand for the RAR/RXR signaling pathway. This pathway is 
one of the key pathways involved in differentiation and is very tightly regulated. Upon 
activation, the RAR/RXR bind to their response elements (RARE) in the promoter of 
specific genes and regulate transcription of genes involved in differentiation, proliferation 
and survival. One such pathway stimulated by the RAR/RXR is the TGF-β signaling 
pathway. 
 
It is classically believed that resident fibroblasts in any tissue become activated during 
wound healing and revert to their inactive state upon resolution150. However, when 
associated with TECs, this activation often become irreversible, leading to formation of 
CAFs. In the pancreas, an injury or insult leads to activation of the PSCs. During the 
course of pancreatic tumor progression, the PSCs become activated by the TECs and 
reach a stage where they presumably become irreversibly activated and drive tumor 
growth. At this point, they express fibroblast activation protein and fibroblast secretory 
protein and become cancer associated fibroblasts or CAFs that cannot go back to the 
quiescent stage. Thus, targeting the CAFs at this stage with molecules that can revert 
the back to “quiescent” state can be considered an attractive therapeutic strategy, as this 
will disrupt the tumor-stroma crosstalk and inhibit the tumor growth and progression. 
	103		
 
Our transcriptomics data showed that treatment of CAFs (isolated from a mature KPC 
mouse tumor) with triptolide deregulated the TGF-β pathway (Figure 4.1) and the 
RAR/RXR signaling pathway. Interestingly, the expression of RBP was increased by this 
analysis and the expression of RDH was downregulated. This indicated that triptolide 
was affecting the retinol-metabolizing pathway. Instead of the retinol being metabolized 
to RA (by RDH), there was more retinol in the CAFs that needed stabilization by RBPs. 
This was confirmed by both our Oil Red staining and vitamin A accumulation assay 
(Figure 4.3). We further observed, this could be that the RAR/RXR pathway is a key 
developmental and differentiation pathway in the cells, it is very tightly regulated. While 
retinoic acid (ATRA and 9cisRA) can stimulate the RAR/RXR transcriptional activity, an 
excess of it acts as an inhibitor of RDH and shuts down the conversion of retinol to RA. 
A number of studies have shown that ATRA can prevent activation of PSCs and this only 
observed at high doses161, 162. Our studies showed that treatment with ATRA at a low 
dose increased proliferation of CAFs, while at an increased dose of 1 uM, it inhibited 
proliferation presumably by causing a feedback inhibition of the RAR/RXR pathway142. 
 
Previous work from our laboratory has shown that Minnelide™, the water-soluble 
prodrug of triptolide, is an effective anti-tumor and anti-stromal compound12. At a dose of 
0.4 mg/kg, Minnelide™ depletes the stroma, induces stromal and tumor cell death, and 
prevents metastasis. However, our recently completed Phase 1 clinical trial shows that 
the maximum tolerated dose of Minnelide™ in patients in 0.67 mg/m2, which translates 
to 0.2 mg/kg in mice. At this dose, Minnelide™ still decreases the ECM in the stroma, 
but does not have any profound effect on viability of TECs or CAFs. In the current work, 
we show that while CAFs promoted tumor growth and invasion, treatment with 
Minnelide™ did not significantly decrease metastasis in vivo142. However, treatment with 
Minnelide™ did result in less number of proliferating cells in the tumor as was seen by 
BrdU uptake142. This effect was confirmed in vitro as well, where treatment with 
conditioned media from triptolide treated CAFs decreased proliferation of TECs as well 
as CAFs (Figure 4.3A). 
 
It is well known that CAFs produce TGF-β, which in turn activates oncogenic signaling in 
the tumor epithelial cells via the SMAD group of transcription factors15, 22. It is also known 
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that TGF-β signaling leads to induction of SP1 transcriptional activity in tumors155. 
Though SP1 is not present is terminally differentiated tissues, we and others have 
shown that pancreatic cancer has an increased SP1 activity163 and its inhibition leads to 
cancer cell death. Our data suggest that triptolide treatment of CAFs leads to inhibition 
of TGF-β mRNA levels as well as its secretion (Figure 4.2). Upon treating MIA PaCa-2 
cells with conditioned media from 25 nM triptolide treated PSCs, we saw a distinct 
decrease in the SMAD transcriptional activity, SP1 expression, as well as SP1 activity 
(Figure 4.5). In addition, other anti-apoptotic pathways that are known to be upregulated 
in pancreatic cancer (and regulated by SP1 activity) were also found to be 
downregulated. 
 
In addition to decreased proliferation, treatment with triptolide also decreased ECM 
secretion by CAFs. Interestingly, all the “inhibitory” effects of triptolide were recovered 
upon treatment with TGF-β, which indicated that triptolide-induced inactivation of CAFs 
led to a decreased TGF-β secretion by these cells, which deregulated both the autocrine 
signaling in the CAFs as well as the paracrine signaling in the TECs.  
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CONCLUSION 
 
The role of CAFs in promoting tumor growth and invasion has been established in a 
number of cancers including pancreatic cancer. Several studies in pancreatic cancer 
have also been focused on depletion of stromal components specifically the ECM. In the 
current study, we show for the first time that Minnelide™, and its active compound 
triptolide, is able to revert the presumably “irreversible” CAFs to an inactive state, where 
they show decreased TGF-β secretion and less ECM production. This in turn affects the 
TECs, and lowers their proliferation and decreases oncogenic signaling, leading to a 
tumor regression. This mechanistic insight on the effect of triptolide on CAF inactivation 
will pave the way for developing viable and attractive therapy for pancreatic cancer, a 
disease that still lacks efficient chemotherapeutic options. 
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METHODS 	
Cell Lines and Cell Culture 
Four primary cell lines were isolated from KrasG12D; Trp53R172H; Pdx-1-Cre (KPC) 
mice. The TECs were isolated according to our previous study153. Isolation of CAFs 
(CAF-1, CAF-5 and CAF-7) from three KPC mice was performed following the protocol 
described by Sharon et al163. The purity of fibroblasts was checked by flow-cytometry 
after staining isolated fibroblasts with fibroblast surface protein (FSP) antibody and CK19 
antibody. Population with FSP+CK19-staining was used for downstream experiments. All 
the established cell lines were used between passages 5 and 18. We also used three 
pre-established cell lines, the mouse PDAC cell line Panc02 and human PDAC cell lines 
MIA PaCa-2 (ATCC), S2-VP10 (a gift from Dr. Masato Yamamoto’s lab, University of 
Minnesota), and the human pancreas fibroblasts SC00A5 (Vitro Biopharma). MIA PaCa-
2, KPC-1, and CAFs were maintained in DMEM (Gibco, ThermoFisher Scientific) 
containing 10% fetal bovine serum (FBS) and 1% Pen Strep (Gibco). Panc02 and S2-
VP10 were cultured in RPMI 1640 (Gibco) containing 10% FBS and 1% Pen Strep 
(Gibco). SC00A5 was maintained in MSC-GRO™ Low serum, Complete Media (Vitro 
Biopharma). All cell lines were routinely tested for mycoplasma and STR profiles 
(ATCC). 
 
Conditioned media (CM) of tumor cells and CAFs was produced using FBS-free basal 
media to exclude the effects of growth factors in serum for downstream experiments. In 
normal conditions, 70% confluent cells were cultured in FBS-free basal media for 48 
hours. In experiments designed to analyze the effects of triptolide, 100% confluent cells 
were cultured in FBS-free basal media containing 25 nM triptolide for 24 hours and then 
changed to no drug, FBS-free, basal media for 48 hours. The resulting CM were 
centrifuged for 10 minutes at 1,000 rpm after collection and stored at -80°C for no more 
than two months before use. 
 
Fluorescence Activated Cell Sorter Analysis 
Single-cell suspensions were prepared from fresh cell culture. Cell fixation and 
permeabilization was performed with the BD Bioscience Cytofix/Cytoperm kit (BD 
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Biosciences), according to the manufacturer’s instructions. Apoptosis and BrDU 
incorporation for proliferation was done using Apoptosis and Cell Proliferation Kit 
following manufacturer’s instructions (BD Biosciences). Analysis of alpha-SMA, TGF-
Beta receptor type 1, and TGFBR2 (Abcam) were conducted by FACS. All samples were 
analyzed on BD FACSCANTO II flow cytometers (BD Biosciences). Data was acquired 
and analyzed with FACSDiVa software (BD Biosciences) and FlowJo Software. 
 
Measurement of ECM and TGF-β Secretion 
To evaluate the effects of triptolide on ECM secretion of CAFs, we measured 
concentration of total collagens, fibronectin (FN), periostin, hyaluronic acid (HA), matrix 
metallopeptidase 2 (MMP2), and MMP9 in CM derived from CAFs. Enzyme-linked 
immuno sorbent assay (ELISA) was used to quantify FN (BioVision), periostin (Thermo 
Scientific), HA (TSZELISA), MMP2 (Abcam), and MMP9 (Abcam). Total collagen was 
quantified by Sircol collagen assay kit (Biocolor Life Science Assays). Meanwhile, 
autocrine signaling of TGF-Beta 1 (Abcam) and TGF-Beta 2 (R&D Systems) were 
determined by ELISA in CM. All the experiments were performed according to the 
manufacturer’s protocol. 
 
Quantitative real-time Polymerase Chain Reaction Assay 
Messenger RNA (mRNA) expression was analyzed through quantitative real-time 
polymerase chain reaction (qRT-PCR) using LightCycler 480 System (Roche) and SYBR 
Green (Qiagen). The 18s ribosomal RNA expression was used to normalize the results 
obtained in different conditions. Primers SP1, HSP70, HSF1, RELA, NFKB1 were 
acquired from Qiagen. Other primers used in this article were listed in Supplementary 
Table 4-1. 
 
Supplementary Table 4-1:  Primers used 
Primers 
for human 
samples Forward Reverse 
18SrRNA GGC CCT GTA ATT GGA ATG AGT C CCA AGA TCC AAC TAC GAG CTT 
TGFB1 GAG CCG TGG AGG GGA AAT TG CCG GTA GTG AAC CCG TTG AT 
TGFB2 CCC TCC GAA ACT GTC TGC C ATG GCA TCA AGG TAC CCA CAG 
TGFB3 ATG ACC CAC GTC CCC TAT CA TCC GAC TCG GTG TTT TCC TG 
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SMAD2 GTT CCT GCC TTT GCT GAG AC TCT CTT TGC CAG GAA TGC TT 
SMAD3 CTG TGG ATG GCT TCA CCG AC GAT GTA GTA GAG CCG CAC GC 
SMAD4 GGG GAC CGG ATT ACC CAA GA AGG TTG TGG GTC TGC AAT CG 
PDGFA TAC TGA ATT TCG CCG CCA CA GAA CAT GGG CGA GGT ATC CG 
PDGFB TTC CTG TCT CTC TGC TGC TAC C CAG CAG GCG TTG GAG ATC AT 
STAT1 GTT ATG GGA CCG CAC CTT CA CAG TGA ACT GGA CCC CTG TC 
SMAD6 AGA GTG ACT GCG AGA CGG T CGC TTC GCG ACT CCG C 
TFEB AGG AGC GGC AGA AGA AAG AC GTC ATT GGC CTT GGG GAT CA 
CDKN2B CGC GGG GAC TAG TGG AGA AG CCA TCA TCA TGA CCT GGA TCG C 
 
Transcriptome Deep Sequencing and Analysis 
Aliquots of RNA were derived from the qRT-PCR samples. CAF-1, CAF-5 and CAF-7 
control group, triptolide short-term treatment group, and long-term treatment group were 
analyzed. The RNA was quality tested using a Bioanalyzer 2100 (Agilent Technologies). 
cDNA was created by reverse transcription of oligo-dT purified polyadenylated RNA and 
fragmented, blunt-ended, and then ligated to barcoded adaptors. Then, the library was 
size selected, and the selection process was validated and quantified by capillary 
electrophoresis and qPCR, respectively. Samples were load on the HiSeq 2500 (Illumina 
Inc.) to generate around 25 million paired-end 50bp reads for each sample. Quality 
control was conducted by FastQC 0.11.2 according to 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc164. TopHat 2.0.5, was used to 
map the paired reads to the UCSC mm10 assembly of the mouse genome165. The mean 
inner distance was established using the insertion size metrics feature of Picard-tools. 
The resulting TopHat data served as input to other Cufflinks tools 2.2.0166. Transcripts 
were also assembled using Cufflinks, with stipulating the reference transcriptome 
Mus_musculus. GRCm38.74. All cufflinks assemblies were merged with Cuffmerge. 
DEGs were calculated with Cuffdiff and presented the data in terms of fragments per 
kilobase of transcript per million mapped reads (FPKMs). Visualization of data from 
Cuffdiff outputs was used CummeRbund v2.0.0141. clusterProfiler167 and Ingenuity 
Pathway Analysis (Qiagen) were used for pathway enrichment analysis. Gene set 
enrichment analysis (GSEA)168 was conducted using app from 
http://www.broadinstitute.org/gsea/index.jsp. Raw data files and processed expression 
files are available online in the Gene Expression Omnibus at 
http://www.ncbi.nlm.nih.gov/geo/ (GenBank Accession Number GSE74490). 
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Estimation of Active and Total TGF-β 
Conditioned media from TECs (MIA PaCa-2 and S2-VP10) and activated pancreatic 
stellate cells (PSC) were collected after 48 hours of plating. Cell lysates from the TECs 
and PSCs were prepared by lysing the cells in RIPA buffer. Total and active TGF-β was 
estimated in the media and cell lysate using LegendMax TGF-b1 ELISA kit and 
LegendMax Free active TGF-b1 ELISA kit (Biolegends). 
 
Vitamin A Accumulation Assay 
5,000 CAF-7 cells were plated in each well of a black 96-well plate with clear bottom. 
The following day, cells were either left untreated, or treated with 25 nM triptolide for 48 
hours. After treatment, 10 ng/mL TGF-β was added for 30 minutes to two untreated rows 
(12 wells), and two rows treated with triptolide (12 wells). After 30 minutes, cells were 
washed gently with PBS, and phenol-free media was replaced. Fluorescence was 
measured with excitation of 300 nm and emission of 338 nm on half of the plate. The 
other half of the plate was used for determining viability, as previously described. 
 
Oil Red Staining 
20,000 CAF-7 cells were plated in each well of a four-well chamber slide. The following 
day, two wells were treated with 25 nM triptolide for 48 hours. After treatment, 10 ng/mL 
TGF-β was added for 30 minutes to one untreated well, and one well treated with 
triptolide. Cells were then washed gently with PBS, and fixed with 2% paraformaldehyde 
for 30 minutes. Cells were washed with water, and incubated with 60% isopropanol/40% 
water for 5 minutes. 60% isopropanol was removed, and replaced with Oil Red O 
working solution (3 parts Oil Red O:2 parts water) for 20 minutes. Cells were again 
washed with water, and counterstained with hematoxylin for 1 minute. Cells were 
washed, mounted with permount, and imaged with a light microscope. 
 
SP1 Activity Assay 
Human pancreatic stellate cells (hPSC) were seeded in four, 10 cm plates, and cultured 
until 70-80% confluent, and were then treated with 25 nM triptolide for 48 hours. 
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Meanwhile, 300,000 MIA PaCa-2 and S2-VP10 cells were seeded in 6 cm plates. After 
48 hours, 10 ng/mL TGF-β was added to one untreated hPSC plate and one triptolide 
treated hPSC plate for 30 minutes. The conditioned media from the hPSCs was 
collected. Any DMEM on the MIA PaCa-2 cells was removed and the cells were rinsed 
with PBS. Conditioned media from the hPSCs was added to the MIA PaCa-2 cells for an 
additional 24 hours as follows: untreated hPSC, hPSC + TGF-β, hPSC + triptolide, and 
hPSC + triptolide + TGF-β. Cell lysates were collected for each sample and added in 
duplicate to the SP1 TransAM ELISA plate (Active Motif). The ELISA was performed per 
the manufacturer’s instructions, and the SP1 binding was normalized to protein 
concentration. 
 
Dual Luciferase Reporter Assay 
MIA PaCa-2 and human pancreatic stellate cells (hPSCs) were plated at a density of 
80,000 cells per well in a 24 well plate. Cells were treated with triptolide (25 nM for 48 
hours) and TGF-β (10ng/ml for 30 minutes). The supernatant from hPSC cells treated 
with triptolide was plated on top of the MIA PaCa-2 cells. After 48 hours of the hPSC 
conditioned media on MIA PaCa-2 cells, the cells were lysed with 1X passive lysis 
buffer. The plate was then kept at -80°C overnight and the luciferase activity was 
measured the next day using the stop and glow kit from Promega according to the 
manufacturer’s protocol. 
 
ECIS 
CAF-7 proliferation was measured by Electric Cell-substrate Impedance Sensing (ECIS). 
CAF-7 cells were seeded in 8W10E+ PET arrays with or without TGF-β (10ng/ml) and or 
triptolide (25 nM). Impedance (Z), capacitance (C) and resistance (R) were monitored for 
60 hours by an ECIS Model Zϴ instrument (Applied BioPhysics Inc.) and normalized to 
Z0.  
 
Statistical Analysis  
Values are expressed as the mean ± SEM. Two-group data were analyzed using a t-
test. Multigroup data were first analyzed using one-way ANOVA, if there are positive 
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findings; Bonferroni's multiple comparisons test was performed to finish pairwise 
comparisons. A p-value< 0.05 was considered statistically significant. 
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DISCUSSION 
 
Summary 
 
Collectively, our studies suggest that the unfolded protein response (UPR) is a complex 
homeostatic mechanism. Depending on the type of stress (hypoxia, nutritional, 
pharmacological), the duration of stress, and the functionality of the UPR, the outcomes 
of endoplasmic reticulum (ER) stress can vary quite significantly.  
 
In Chapter 1 we have shown that chronic ER stress can occur when glucose regulatory 
protein 78 (GRP78), the master regulator of the UPR is depleted. Our study shows that 
downregulating specificity protein 1 (SP1), a transcription factor that is overexpressed in 
pancreatic cancer, activates UPR, and results in chronic ER stress. We have shown that 
SP1 downregulation is responsible for inadequate UPR signaling, by preventing GRP78 
from being transcribed. Further, we show that both inhibition of SP1 and well as inducing 
chronic ER stress (with known pharmacological agents), lead to lysosome membrane 
permeabilization (LMP), a sustained accumulation of cytosolic calcium, and eventually 
cell death in pancreatic cancer. 
 
Using a pharmacological agent to induce ER stress is potentially a useful strategy for 
killing cancer cells, particularly when used in combination with chemotherapeutics with 
other targets. The use of bortezomib, a proteasome inhibitor that causes ER stress and 
proteotoxicity through caspase-4 activation, has been evaluated clinically for cancer 
treatment 169, 170. Bortezomib alone has shown to be effective in hematological 
malignancies; however, in solid tumors it showed minimal effects 170-172. Bortezomib and 
gemcitabine combination demonstrated synergistic effects in solid tumors173. 
Pharmacological agents do not always result in cancer cell death, which is why 
understanding mechanisms of action is incredibly valuable. For example, in breast 
cancer, some therapies (tamoxifen and faslodex) actually induce acute ER stress, which 
promotes cell survival and drug resistance128. 
 
In an acute stress scenario, we and others have shown that cancer cells upregulate 
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multiple UPR components in order to keep up with the nutrient and biosynthetic 
demands of tumor cells. In Chapter 2, we have shown that basal levels of SP1, GRP78, 
nuclear factory, erythroid 2-like 2 (NRF2), and multiple ATP-binding cassette (ABC)-
transporters are overexpressed in pancreatic cancer. SP1 and GRP78 are responsible 
for upregulating pro-survival pathways. NRF2 has been reported to upregulate certain 
ABC-transporters, as well as decrease the amount of reactive oxygen species (ROS) 
produced by cells, which are both know mechanism of drug resistance. As a result, we 
have shown that transiently silencing GRP78 or SP1 pushes the cancer cells towards a 
chronic ER stress phase. We therefore achieve less efflux activity by ABC-transporters 
and greater ROS production (a loss of protection), thereby increasing sensitivity to 
otherwise resistant drugs. 
 
While transient silencing of gene expression is useful in certain mechanistic studies, it 
can contrast with gene expression that occurs in long-term silencing. Modulation of long-
term gene expression (via shRNA, CRISPER, or animal knockouts) can lead to the 
activation of long-term compensatory signaling and/or secondary modulations. For 
example, stable cell lines have been generated that have been exposed to long-term 
oxidative stress, and resistant cells were selected and propagated174, 175. Further, it has 
been shown by Lee et al. that the proteome of hypoxic cells is completely different than 
cells grown in normoxia 176, 177.  Since a transient reduction in a protein may have a 
completely different effect than the long-term removal of a protein, we next looked at 
using a stable-sh cell line for GRP78 in Chapter 3. We have concluded that the stable 
shGRP78 cells have a very different proteomic profile. While the shGRP78 cells are 
viable, they proliferate at a slower rate. Additionally, these cells have reduced stemness 
properties (colony formation, invasion). 
 
Pancreatic cancer characteristically has a dense, desmoplastic stroma. The stroma 
creates hypoxic niches, and results in a pro-inflammatory environment that aids in tumor 
progression and confers chemoresistance. In Chapter 4, we focused on the tumor 
epithelial and stroma interactions. By using a pharmacological inhibitor, Minnelide™, we 
found an inactivation of the cancer-associated fibroblasts (CAFs), which have previously 
been thought to be terminally-activated. These inactivated CAFs secreted less 
transforming growth factor-beta (TGF-β) and produced less extracellular matrix (ECM). 
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This decreases CAF proliferation and oncogenic signaling, leading to tumor regression. 
 
Our studies suggest that SP1 and GRP78 could be potential targets for future 
therapeutics in PDAC. These mechanistic studies on the effect of triptolide/Minnelide™ 
ER stress, UPR activation/inactivation, CAF inactivation, and cell death will pave the way 
for developing a viable and attractive therapy for pancreatic cancer, a disease that still 
lacks efficient chemotherapeutic options. 
 
Future Directions 
 
The third chapter of this dissertation is an incomplete study at this time, because the 
preliminary findings suggest that ER stress plays an essential role in cancer stem cell 
maintenance. There currently are few studies that describe a role of the UPR in 
stemness, and no current study suggesting a direct link between cancer stem cells and 
the UPR. One tool that I was working on making, which would be instrumental in 
answering these questions, is an inducible-GRP78 knockdown system. I have cloned a 
shGRP78 sequence into a pLKO-Tet-on-neo backbone, packaged them in a Lenti-viral 
system, and transduced my cell line of choice (S2-VP10). I am currently propagating the 
clonal populations into stable inducible cells. Eventually, these cells will be able to be 
used for the same in vitro and in vivo studies, as well as others. We have multiple follow 
up questions to the studies which I have presented in this dissertation.  
1. Is GRP78 required for stemness, and therefore tumor initiation? 
2. Is there a delay in tumor initiation when tetracycline/doxycycline is added to the 
pLKO-Tet-on-shGRP78 cells? 
3. After tumor initiation, does pLKO-Tet-on-shGRP78 still have an effect on tumor 
reduction, and weight? 
3. In advance tumor status, are pLKO-Tet-on-shGRP78 cells more sensitive to 
traditional therapies used in pancreatic cancer (gemcitabine, 5-FU, paclitaxel)? 
Additionally, these cells will be useful in metabolomics studies, since UPR components 
have been linked with the hexosamine biosynthetic pathway and glucose uptake. 
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CONCLUSIONS 
 
Endoplasmic reticulum (ER) stress initiates an important mechanism for cell adaptation 
and survival, named the unfolded protein response (UPR). Severe or chronic/prolonged 
UPR can breach the threshold for survival and lead to cell death. This dissertation has 
the central theme of ER stress, and the homeostatic mechanism of the UPR in 
pancreatic cancer.  
 
My first study focused on how the UPR could be pushed to the chronic stage, and the 
cell death mechanisms that follow. The current study identified specificity protein 1 (SP1) 
and glucose regulatory protein 78 (GRP78) as potential targets for future therapeutics in 
pancreatic ductal adenocarcinoma (PDAC); discovered a protective role of SP1 in 
cancer; as well as further detailed ER stress response in cell death mechanisms. 
 
The second study in this dissertation addresses acute ER stress in cancer. It has been 
well documented in cancer that cancer cells utilize the UPR to their growth and survival 
advantages, which can also aid in drug resistance. This study identifies some of the drug 
resistance mechanisms utilized by pancreatic cancer cells, and how targeting the UPR 
directly with siGRP78 or indirectly with siSP1 both result in chemosensitivity.  
 
My third study further explores the roles of the UPR in pancreatic cancer, by utilizing a 
stable cell line with GRP78 knocked down. The transcriptomic and proteomic studies 
confirm that GRP78 is an essential protein in maintaining cellular homeostasis. The 
shGRP78 cells display significantly slower proliferation, lipid dysregulation, and a 
decrease in stemness and self-renewal properties. Further, GRP78 knock down delays 
tumor initiation and decreases tumor growth.  
 
The final study included in this dissertation showed for the first time that Minnelide™, 
and its active compound triptolide, is able to revert the “irreversible” cancer-associate 
fibroblasts (CAFs) to an inactive state. Inactivated CAFs showed decreased 
transforming growth factor-beta (TGF-β) secretion and less extracellular matrix (ECM) 
production. This in turn affects the tumor epithelial cells (TECs), and lowers their 
proliferation and decreases oncogenic signaling, leading to a tumor regression. 
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